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ABSTRACT 
KELLY RONEY: The Role of Plexin-B2 in the Immune System                                                                                              
(Under the direction of Dr. Jenny P.-Y Ting) 
                                                               
Plexins and semaphorins are a family of transmembrane proteins that mediate diverse roles 
such as cell-cell contact, cell adhesion, cell movement, and cell response.  Plexins and 
semaphorins are unique from other proteins in containing a conserved extracellular 
semaphorin domain.  Semaphorins are smaller than plexins and have short intracellular tails.  
Plexins are larger and have long intracellular tails that are involved in intracellular signaling.  
The majority of plexin and semaphorin research has focused on the nervous system since 
their discovery in the late 1980’s.  Recently plexins and semaphorins were discovered in the 
immune system, where they play similar roles similar to those of the nervous system for cell 
guidance.  However, the receptor ligand pairs for semaphorins and plexins in immune system 
are distinct from those in the nervous system, and plexins and semaphorins have been found 
to mediate many immune specific cell processes including T cell activation and cytokine 
response.  The B subfamily of plexins has been found to mediate cell movement through 
activation and deactivation of the Rho family of small GTPases.  The majority of B family 
plexin studies have focused on Plexin-B1 in cell lines or the nervous system.  The data in this 
thesis show that Plexin-B2, and understudied B family plexin, is expressed on cells of the 
innate immune system in-vivo.  Plexin-B2 regulates cell velocity, activation of Rho family 
members Cdc42 and Rac, and cytokine secretion in macrophages and dendritic cells. 
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Chapter 1: Introduction 
 
1.1 Significance 
 
Plexins and semaphorins are a large family of proteins that are involved in cell 
movement and response.  The importance of plexins and semaphorins has been emphasized 
by their discovery in many organ systems including the nervous (reviewed in Negishi et al. 
2005), epithelial, (Miao et al. 1999; Fujii et al. 2002), and immune systems (reviewed in 
Kumanogoh et al. 2003; Takegahara et al. 2005) as well diverse cell processes including 
angiogenesis (reviewed in Klagsbrun et al. 2005), embryogenesis (Perala et al. 2005), and 
cancer (reviewed in Chedotal et al. 2005).  Our lab has identified a novel plexin in the 
immune system, Plexin-B2, which is expressed on dendritic cells and macrophages and plays 
a role in the immune response. 
Plexins and semaphorins are transmembrane proteins that share a conserved 
extracellular semaphorin domain of approximately 500 amino acids (reviewed in Gherardi et 
al. 2004; Kruger et al. 2005).  The plexins and semaphorins are divided into eight and four 
subfamilies respectively based on deoxyribonucleic acid (DNA) sequence similarity.  
Semaphorins are relatively small proteins containing the semaphorin domain and short 
intracellular tails, and often serve as the ligand for plexin receptors.  Plexins contain the sema 
domain, as well as the extracellular met related sequence (MRS) domain and long 
intracellular tails containing a Sex and Plexin (SP) domain (Maestrini et al. 1996; Bork et al. 
1999; Tamagnone et al. 1999; Kruger et al. 2005).  
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The majority of plexin and semaphorin research has focused on the nervous system, 
particularly the developing nervous system, and most studies are in-vitro.  Plexins and 
semaphorins are thought to mediate many common neuronal cell processes including cell 
movement, dendrite extension and repulsion, cytoskeletal rearrangement, and signal 
transduction (reviewed in Cohen 2005; Masuda et al. 2005; Negishi et al. 2005).  Many 
neuronal cell processes are similar to those found in cells of the immune system.  Both cell 
types must be able to move within the body in a directional pathway, make and maintain 
contact with other cells, communicate across cell contact sites, and respond to both 
intracellular and extracellular cues in order to facilitate these maneuvers.  Though historically 
studied in the nervous system or cell lines, plexins and semaphorins have been recently found 
to play critical roles in the immune system. 
Our lab has historically studied Plexin-A1, which, unlike any other plexins found to 
date, is under the control of the major histocompatability complex (MHC) class II 
transactivator (CIITA) and is expressed only in dendritic cells in the immune system (Wong 
et al. 2003).  RNA interference of Plexin-A1 in dendritic cells reduced dendritic cell 
mediated T cell activation by 90% (Wong et al. 2003).  The Plexin-A1 ligand Sema6D is 
required for CD127 expression, which is critical for late phase T cell development (O'Connor 
et al. 2008). 
 Our group has recently identified another plexin, Plexin-B2, on in-vitro bone marrow 
derived dendritic cells (BMDCs) by gene microarray profiling.  Originally identified in 
human brain tumors in 1995 (Shinoura et al. 1995), Plexin-B2 is a 206 kD protein that 
contains a furin-like proprotein convertase cleavage site found only in the Plexin B subfamily 
(Tamagnone et al. 1999), suggesting Plexin-B2 is capable of both long and short range 
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signaling as it can be both membrane bound and secreted.  Plexin-B2 is expressed in the 
developing mouse nervous system (Worzfeld et al. 2004), stimulates neurite growth and 
induces cell aggregation through trans-homophilic interactions (Hartwig et al. 2005).  In 
transfection experiments with human HEK293T cells, full-length Plexin-B2 is cleaved and 
heterodimerizes at the cell surface (Artigiani et al. 2003), interacts with the Scatter Factor 
Receptors Met and Ron (Conrotto et al. 2004), and binds to overexpressed Sema4D (Fig. 1.4) 
(Masuda et al. 2004). 
 Our finding of Plexin-B2 gene expression in mouse dendritic cells and macrophages 
provides evidence of a plexin previously unreported in the innate immune system.  We have 
also found that the expression level of Plexin-B2 is modulated throughout cell maturation, 
which suggest that Plexin-B2 may play a regulatory role in the life cycle and activation of the 
dendritic cells and macrophages.   We have found the Plexin-B2 is a negative regulatory of 
cell motility through negative regulation of the small GTPases Rac and Cdc42. 
 
1.3 Plexin and Semaphorin Biology 
1.3A.  Discovery of Plexins and Semaphorins. 
Semaphorins and their receptors, plexins, are a large family of transmembrane 
proteins that share a conserved semaphorin domain.  Semaphorins and plexins are thought to 
mediate cell guidance and movement through attractive and repulsive cues.  A group of 
proteins that mediate cell movement was first hypothesized by R.W. Sperry in his 
chemoaffinity hypothesis for nerve fiber growth (1963).  This hypothesis was later supported 
by time lapse video of retinal ganglion growth fibers extending towards the optic tectum in 
Xenopus laevis embryos (Harris et al. 1987).  Proteins thought to be involved in guidance 
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were detected that same year in Xenopus optic tectum by monoclonal antibodies which are 
today known to recognize Plexin-A1 and neuropilin-1 (Takagi et al. 1987; Ohta et al. 1992; 
Fujisawa 2004).  The first semaphorin was identified as such in 1993 (Luo et al.), and this 
lead to the discovery that semaphorins are a family of proteins based on homology of a 
common extracellular semaphorin domain (Luo et al. 1995).  The semaphorin family was 
later expanded to include the semaphorin receptor proteins named plexins, which contain the 
semaphorin domain as well as an additional intracellular plexin domain (Ohta et al. 1995; 
Satoda et al. 1995; Maestrini et al. 1996; Comeau et al. 1998).  Currently at least 30 
semaphorins and nine plexins have been identified.  
 
1.3B.  Plexin and Semaphorin Structure  
 The semaphorin family is divided into eight subclasses based on phylogenetic 
analysis and protein structure by the Semaphorin Nomenclature Committee (1999).  All 
subclasses contain an approximately 500 amino acid conserved sema domain (reviewed in 
Kolodkin et al. 1993; Gherardi et al. 2004).  Many of the semaphorins also contain a 
cysteine-rich domain termed plexins, semaphorins, and integrins (PSI) or MRS (Bork et al. 
1999; Tamagnone et al. 1999).  The first two subclasses, classes I and II, are invertebrate 
semaphorins. Classes III- VII are vertebrate semaphorins, and class VIII are viral 
semaphorins.  Class III and IV are distinct in that they can be secreted.  Class V semaphorins 
have seven thrombospondin repeats, and class VII semaphorins are 
glycosylphosphatidlinositol (GPI)-linked to the cell membrane.  Class VI semaphorins are 
prototypical in that they contain only the sema domain, transmembrane domain, and a short 
cytoplasmic domain.   
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 Like semaphorins, plexins are single pass transmembrane proteins containing an 
extracellular semaphorin domain, although this domain in plexins is less conserved.  Unlike 
semaphorins, plexins contain three cysteine rich extracellular domains homologous to scatter 
factor receptors called MRS, an immunoglobulin-like fold shared by plexins and 
transcription factors (IPT) domain, as well as a long cytoplasmic tail containing an SP 
domain (Maestrini et al. 1996; Tamagnone et al. 1997; Bork et al. 1999).  The plexin domain 
is a highly conserved 600 amino acid region that shares no homology to any other known 
domains and mediates signaling through a pathway that has not yet been fully elucidated. 
Plexins are found in vertebrates, invertebrates, viruses and bacteria and are divided 
into four subfamilies based on their DNA sequence (Tamagnone et al. 1999).  The plexin 
family consist of subfamilies A (members A1-A4), B (members B1-B3), C (member C1), 
and D (member D1) (reviewed in Tamagnone et al. 1999).  All subfamilies contain 
transmembrane proteins, and subfamilies A and B also contain secreted proteins. 
The receptor and ligand pairs that mediate semaphorin and plexin signaling have been 
studied extensively however they vary greatly by cell type, leading to some confusion.  
Plexins often serve as receptors for semaphorins, and are sometimes coupled with the co-
receptor neuropilin (Takahashi et al. 1999; reviewed in Tamagnone et al. 1999; reviewed in 
Fujisawa 2004).  However, the receptor ligand roles are dynamic due to the ability of both 
plexins and semaphorins to be membrane bound or secreted, transmit signals intracellularly, 
or bind to other types of proteins and form co-receptors.  Semaphorin and plexin roles are 
further complicated by the ability of these proteins to act as either repulsive or attractive 
cues, with the type of signal depending on the receptor-ligand pair, developmental stage of 
the organism, cell type, and/or cellular context (Kantor et al. 2004) .    
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The majority of semaphorin and plexin research has focused on the nervous system, 
particularly the developing nervous system.  The distal tip of growing neurons is easily 
studied, very sensitive to small amounts of signal, and thought to grow and extend relative to 
cytoskeletal rearrangement (reviewed in Goshima et al. 2002).  Plexins and semaphorins play 
both attractive and repulsive roles in neurons, and often lead to cytoskeletal rearrangement 
thought to be mediated by several different signaling pathways including regulation of the 
Rho family of GTPases and integrin regulation (Driessens et al. 2001; Oinuma et al. 2004; 
Tamagnone et al. 2004).   Recently, the importance of plexins and semaphorins in basic cell 
movement and cellular response has been emphasized by their discovery in other organ 
systems and processes including the epithelial system (Miao et al. 1999; Fujii et al. 2002) , 
angiogenesis (Serini et al. 2003; Shoji et al. 2003; Conrotto et al. 2005), embryogenesis 
(Perala et al. 2005), and the immune system (Takamatsu et al. 2010). 
 
1.3C.  Plexins and Semaphorins in the Immune System 
 The immune system and nervous system share many commonalities.  Cells in both 
systems need to be able to move within the body in a directional pathway, make contact and 
communicate with other cells, and respond to environmental cues.  Plexins and semaphorins 
have been implicated in many of these processes, although the exact role for these proteins 
and how they signal is not yet fully understood. 
 Semaphorin 4D (Sema4D), also known as CD100, is the most studied protein of the 
semaphorins and plexins in the immune system and is a good example of the complex 
pathways involving these proteins.  Sema4D is a 150-kDa cell surface protein that exist as a 
homodimer on most hematopoietic cells (except red blood cells and platelets) and contains 
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both a semaphorin domain and a Ig-like domain in its extracellular region (Bougeret et al. 
1992; Herold et al. 1995).  In T cells, Sema4D associates with CD45 at the cell surface and 
increases homotypic cell adhesion, while stimulation of CD45 or cellular proteolysis leads to 
the release of a soluble form of Sema4D (Herold et al. 1996; Elhabazi et al. 2001).  There is 
also evidence that in human T and NK cells, the cytoplasmic domain of Sema4D interacts 
with a serine-threonine kinase (Elhabazi et al. 1997).  Soluble, dimerized Sema4D is capable 
of inhibiting the spontaneous migration of B cells and monocytes (Delaire et al. 2001).  
Sema4D expression leads to B-cell aggregation, differentiation, and improved viability in-
vitro (Hall et al. 1996), and associates with protein tyrosine phosphatase activity (Billard et 
al. 2000).  The receptor for Sema4D in lymphocytes has been identified as CD72 
(Kumanogoh et al. 2000), which is in contrast to its receptor in the endothelial and nervous 
systems, Plexin-B1 (Tamagnone et al. 1999; Conrotto et al. 2005).  The binding of Sema4D 
to CD72 is thought to promote B cell proliferation and differentiation by abrogating the 
negative effects of CD72 (reviewed in Kumanogoh et al. 2001; Kumanogoh et al. 2004).  In 
Sema4D deficient mice, CD5+ B1 cells are decreased, and in-vitro proliferative responses in 
B cells were reduced compared to wild type mice (Shi et al. 2000).  Dendritic cells from 
Sema4D deficient mice were unable to display co-stimulatory molecules (Kumanogoh et al. 
2002). 
 Other semaphorin and plexin family members have been found in the immune system 
but their biological roles are only partially understood.  Semaphorin 4A (Sema4A) is similar 
in structure to the above-described Sema4D.  Sema4A is found on B cells and dendritic cells 
and enhances activation of T cells through the receptor Tim-2 (Kumanogoh et al. 2002).  
Semaphorin 3A (Sema3A) inhibits immune cell migration, similar to the inhibition of 
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migration by Sema4D (Delaire et al. 2001).  Semaphorin 7A (Sema7A), whose function is 
unknown, is a GPI-anchored protein with high homology to viral semaphorin and is found on 
activated lymphocytes (Xu et al. 1998; Yamada et al. 1999).  Mouse dendritic cells express 
Plexin-C1.  When engaged by its poxvirus semaphorin ligand (A39), Plexin-C1 inhibits cell 
adhesion, spreading, and migration and induces actin cytoskeleton rearrangement (Walzer et 
al. 2005).  Plexin-A1 is under the control of CIITA and is expressed only in dendritic cells 
(Wong et al. 2003).  Reducing the amount of Plexin-A1 by RNA interference in dendritic 
cells reduced T cell activation by 90% without affecting antigen binding and presentation 
(Wong et al. 2003).  
 Plexin-B2, the focus of this thesis, has been identified but not studied in the immune 
system.  Because the role of Plexin-B2 is not well understood, both Plexin-B2 and its closely 
related but better-studied family member, Plexin-B1, will be reviewed.  Plexin-B1 research 
has served as the basis for the hypothesis that have guided the research into the immune 
system function of Plexin-B2.  Plexin-B1 is a cell surface protein that mediates many of its 
functions through Rho family of small G proteins.  Therefore G proteins will briefly be 
reviewed before proceeding to the biology of the B family of plexins. 
 
1.4 G Protein Biology 
Guanosine nucleotide-binding proteins (G proteins) are found in cells within every 
system of the body.  G proteins consist of two main families: large and small G proteins.  
Large G-proteins are composed of α-, β-, and γ subunits and are also called heterotrimeric G 
proteins.  Small G-proteins, also referred to as low-molecular-weight G (LMWG) proteins, 
consist of only one unit.  Both large and small G proteins cycle between an active, GTP-
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bound state and an inactive, GDP bound state and serve as molecular switches (Fig. 1.1).  G 
proteins have intrinsic ability to hydrolyze GTP to GDP and are referred to as GTPases, but 
this reaction rate is generally slow.  The rate of GDP/GTP binding is controlled by GTPase- 
activating proteins (GAPs) and guanine-nucleotide exchange factors (GEFs).  GAPs 
accelerate the intrinsic GTPase ability of the G protein, and thus downregulate G protein 
signaling.  GEFs serve the opposite function and accelerate the exchange of GDP for GTP 
and upregulate G protein signaling.  Control of G protein signaling can also be regulated 
spatially by guanine nucleotide dissociation inhibitors (GDIs), which bind and inhibit 
GTPases by preventing them from binding to the cell membrane, and thus spatially prevent 
them from interacting with their downstream partners and signaling.  Control of G proteins is 
very finely tuned and very complex.  The Rho subfamily alone has to date over 70 GEFs and 
60 GAPs to regulate their on/off state, and each of these regulators is in-turn controlled by 
other proteins (reviewed in Etienne-Manneville et al. 2002; Siderovski et al. 2005; 
Tybulewicz et al. 2009).  
To date, Plexins have been found to interact with only small G proteins.  Small G-
proteins are a family of proteins containing 50 members, and is referred to as the Ras 
superfamily.  This family is further divided into five subfamilies: 1) Ras, 2) Rho, 3) Rab, 4) 
Arf, and 5) Ran families (reviewed in Scheele et al. 2007).  Of these subfamilies, the B 
plexins have been found to interact with small G proteins of the Ras and Rho families and  
the GEFs, GAPs and GDI’s that modulate their activation. 
 
1.4A.  Ras Subfamily of Small G Proteins 
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Proteins of the Ras subfamily members includes H-, K-, M-, N-, and R-Ras, Rheb, 
and Rap.  The Ras superfamily must be either extracellular or intracellular membrane linked 
to function, and have gained considerable attention due to their roles as oncogenes.  Ras 
activating mutations are found in 30% of human cancers, and thus Ras has been targeted for 
therapeutic intervention (reviewed in Calvo et al. 2010).  Ras proteins are capable of 
translocating between cellular membranes, and Ras localization is thought to be a major 
method of control of Ras signaling.  Similar to other Ras superfamily members, Ras 
activation can also be controlled by GEFs and GAPs (reviewed in Scheele et al. 2007; Calvo 
et al. 2010). 
Ras is linked to the extracellular-regulated kinase (ERK) signaling pathway and its 
control of cell proliferation and survival.  Mutations in the Ras subfamily are linked to 
Noonan syndrome, a form of dwarfism with overgrowth of cells, Costello syndrome, in 
which cells grow in a constitutive manor, and Cardio-facio-cutaneous syndrome, which is 
characterized by abnormal cell growth (reviewed in Roberts et al. 2007; Lau et al. 2009).  
Ras mutations have been specifically linked to pancreatic, thyroid, colon, neuronal, liver, 
skin, and lung cancers with many other types of cancer linked to mutations in the Ras-ERK 
pathway (reviewed in Roberts et al. 2007).  The Ras-ERK pathway has therefore been 
targeted by many pharmaceutical companies in the treatment of cancer.  Ras family proteins 
have also been linked to T cell receptor and IL-2 receptor stimulation and subsequent cell 
proliferation and cytokine gene induction (reviewed in Scheele et al. 2007). 
 
1.4B.   The Rho Subfamily of GTPases 
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The Rho subfamily consists of 23 proteins.  The members Ras-related C3 botulinum 
toxin substrate 1 (Rac1), cell division cycle 42 (Cdc42), and Ras homologue gene family 
member A (RhoA) are the most well studied of the group.  This subfamily is distinct in that it 
contains some atypical members, including Rnd, that are not cycled between the GTP/on and 
GDP/off for regulation, and are instead thought to be regulated by expression or stability 
(reviewed in Etienne-Manneville et al. 2002; Tybulewicz et al. 2009).  The Rho family of 
GTPases mediates cell shape, migration, and adhesion as well as other cell processes 
including cell activation, proliferation, and survival.  For example, in hematopoietic stem and 
progenitor cells (HSC/Ps), Cdc42 and Rac deletional mutants show a loss of proliferation and 
increased apoptosis, as well as defects in adhesion, migration, and homing capabilities.  T 
and B cells deficient in Cdc42 or Rac also display defects in proliferation, survival, 
migration, and adhesion (reviewed in Mulloy et al. 2010).  In macrophages, Rac and Cdc42 
are implicated in Fcγ receptor-mediated phagocytosis as well as migration, cell shape, and 
adhesion (reviewed in Ridley 2008; Mulloy et al. 2010).  Rac, Rho, Rnd, and Ras, as well as 
other GTPases, have been linked to B family plexins. 
 
1.5 The Biology of B Family Plexins 
The B family plexins are one of the four main plexin families, A-D.  The B plexin 
family is composed of three members, Plexin-B1, B2, and B3 (Fig. 1.2).  The B family 
plexins show the highest homology to the scatter factor receptor family, which is a family of 
transmembrane receptors that lead to invasive growth and are often linked to cancer 
(Maestrini et al. 1996; Conrotto et al. 2004).  All Plexin-B family members share the protein 
domains common to all plexins, including the extracellular semaphorin and MRS [also called 
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plexins, and semaphorins, and integrins (PSI)] domains, and the three intracellular 
immunoglobulin like fold, plexins, transcription factors (IPT) domains, followed by the 
Plexin Cytoplasmic RasGAP domain (also known as SP domain).  Plexin-B1 and B2 have a 
distinct protein domain that separates them from the other plexins, the furin-like protease 
domain, which are thought to facilitate cleavage by proteases (Tamagnone et al. 1999). 
Plexin-B1 was the first of this family identified, and has been the most extensively 
studied, particularly in its role as a regulator of the Rho family of small GTPases.  Thus, 
Plexin-B1 is a model B family plexin from which hypothesis can be generated for other B 
family plexins.  A critical review of Plexin-B1 biology and roles in the immune system 
allows for comparisons between Plexin-B1 and Plexin-B2 and highlights unanswered 
questions for Plexin-B2 and the B family of plexins. 
 
1.6 Plexin-B1 Biology 
1.6A. Plexin-B1 and RacGTPase 
In Drosophila, which has only one B family plexin, Plexin-B has been found to bind 
and inhibit only active, GTP-bound Rac and enhance RhoA signaling at the same time, 
suggesting that Plexin-B in this system functions to fine tune the Rho family GTPase 
signaling (Hu et al. 2001).  The binding of Plexin-B1 to Rac-GTP but not Rac-GDP to has 
been found for Plexin-B1 and B2 in vertebrates, and thus this function of the B family 
plexins is conserved across species (Fig. 1.3) (Rohm et al. 2000; Vikis et al. 2000; Driessens 
et al. 2001).  Plexin-B1 binds to activated Rac via a sequence that is partially homologous to 
the CRIB (Cdc42/Rac interactive binding) domain in the Plexin-B1 cytoplasmic tail (Vikis et 
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al. 2000; Driessens et al. 2001).  This domain binds to the switch I region (effector domain) 
of Rac (Vikis et al. 2000).    
The function of Plexin-B1 binding to active Rac is poorly understood.  In Drosophila 
Plexin-B, dosage assays suggest that Plexin-B inactivates Rac, yet how this occurs has not 
yet been determined (Hu et al. 2001).  In HEK293T cells Plexin-B1 inhibition of Rac 
signaling is accomplished by binding of activated Rac to Plexin-B1 and sequestering it away 
from its downstream effector p21-activated kinase (PAK), though the phenotypic 
consequence of Plexin-B1 Rac sequestration from PAK is not reported (Figure 3) (Vikis et 
al. 2002).  It has also been suggested that Plexin-B1 could function directly as a Rac GEF 
(Rohm et al. 2000; Hu et al. 2001; Vikis et al. 2002).   However, extensive structural studies 
of Plexin-B1 have suggested that it does not function as a RacGAP (Bouguet-Bonnet et al. 
2008).  Bouguet-Bonnet et al. have demonstrated that the GTP binding state of Rac does not 
change in response to titration of Plexin-B1, and thus the role of Plexin-B1 is likely that of an 
effector of Rac but not a direct GAP (2008).  These structural studies have also suggested 
that Rac binds to only undimerized Plexin-B1, and that the Rac-Plexin-B1 interaction is 
temperature and pH dependant (Hota et al. 2009; Tong et al. 2009).  Human prostate cancer 
clinical samples have been found to have mutations in Plexin-B1 Rac binding site (Wong et 
al. 2007).  These mutations, when cloned and overexpressed in HEK293T cells, upregulate 
active Rac and increased cell motility, invasion, and adhesion (Wong et al. 2007).  Together 
these data suggest that regulation of Plexin-B1, and regulation of the small GTPases by 
Plexin-B1, is very finely tuned by temperature, pH, dimerization state of Plexin-B1 by its 
ligand, and cell type. 
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Interestingly the binding of activated Rac to Plexin-B1 enhances the amount of 
Plexin-B1 and its localization to the cell surface, suggesting bidirectional signaling, and is, 
according to the authors, the first known example of a small GTPase directly regulating the 
function of a receptor (Vikis et al. 2000; Vikis et al. 2002).  Biochemical experiments using 
one of the ligands for Plexin-B1, Sema4D, have shown that ligand binding to Plexin-B1 
enhances the interaction of Plexin-B1 and Rac (Vikis et al. 2000).  
Plexin-B1 binding to activate Rac has been confirmed in many papers and across 
species, suggesting that this is likely an important function of Plexin-B1 and other B family 
plexins.  The Plexin-B1-Rac interaction has been shown to function to downregulate Rac, 
although the mechanism is unknown.  Future studies should explore how this downregulation 
occurs, what ligand binding state or dimerization state of Plexin-B1 is required for this 
downregulation, and determine the phenotypic consequences. 
 
1.6B. Plexin-B1 and its Effects on Rho Activation 
Unlike Rac, which is bound by Plexin-B1 only in its active, GTP-bound state, both 
RhoA-GDP and RhoA-GTP interact with Drosophila Plexin-B (Hu et al. 2001).  Studies in 
mammalian and yeast cells lines have shown that Plexin-B1, B2 and B3 but not A2 and D1 
bind to Rho guanine nucleotide exchange factors (RhoGEFs) containing a post synaptic 
density protein, Drosophila disc large tumor suppressor, and zonula occludens-1 protein 
(PDZ) domain instead of directly to Rho (Ranganathan et al. 1997; Hu et al. 2001; Driessens 
et al. 2002).  The Plexin-B family control of Rho is mediated through dimerization of the 
PDZ domain found in the Plexin-B cytoplasmic tail with the PDZ domain of the RhoGEFs 
PDZ-RhoGEF and Leukemia-associated RhoGEF (LARG) (Hu et al. 2001).  PDZ 
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dimerization results in cell rounding and retraction and the formation of stress fibers in 
overexpression studies in Swiss3T3 fibroblast and in HEK293T cells (Hu et al. 2001; 
Aurandt et al. 2002; Driessens et al. 2002).  The binding of Plexin-B1 to PDZ-RhoGEF and 
LARG in primary hippocampal neurons and retinal ganglion leads to growth cone collapse in 
response to Sema4D (Swiercz et al. 2002).  In COS-7 cells it has been shown that a direct 
interaction between Plexin-B1 and another Rho family member, Rnd1, amplifies the 
interaction of Plexin-B1 and Rho, and thus Plexin-B1 is modulated by a Rho family member 
(Oinuma et al. 2003).   In-vivo experiments in using Plxnb1-/- mice demonstrate that long 
term, Sema4D induces dendrite branching in hippocampal neurons post the immediate effect 
of growth cone collapse (Vodrazka et al. 2009).   
 Intriguingly, Plexin-B1 interacts with p190RhoGAP in a ligand dependant manner 
and can thus downregulate Rho (Barberis et al. 2005).  This suggests that Plexin-B1 is well 
positioned and equipped to respond to environmental cues and down- or up-regulate Rho as 
needed.  
Plexin-B1 Rac and Rho binding are separate events.  Studies with mutated Plexin-B1 
that does not contain the Rac binding domain show that it can dimerize and activate Rho 
normally (Driessens et al. 2001).  This finding is supported by structural studies which 
suggest that Rac1 binding is not compatible with Plexin-B1 dimer formation, and thus 
ligand-induced Rho activation similar to wild type Plexin-B1 (Hota et al. 2009).  Additional 
studies of overexpressed Plexin-B1 in 3T3 cells suggest that undimerized Plexin-B1 does not 
affect cell morphology, and that clustering of the cytoplasmic domain of Plexin-B1 by ligand 
is required for cell contraction and stress fiber formation (Driessens et al. 2001).   
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1.6C.  Plexin-B1 and Ras GAP Activity 
 In a pivotal 2004 paper, Plexin-B1 was shown to have yet another function in 
modulating the Rho family of GTPases: Ras-GAP (Oinuma et al.).  Previous studies had 
noted homology between the intracellular domains of Plexin-B1 and Ras-GAPs at two 
conserved arginine residues (Rohm et al. 2000; Hu et al. 2001).  Oinuma et al. found that 
Plexin-B1 directly interacts with the active, GTP bound from of the Rho family member R-
Ras (2004).  This interaction depends on the binding of Plexin-B1 to the Rho family member 
Rnd1 and results in the activation of the intrinsic GTPase ability of R-Ras in a ligand 
dependant manner in both overexpression studies with COS-7 cells and studies of 
endogenous Plexin-B1 in PC12 cells (neuroendocrine tumor cell line) (Oinuma et al. 2004).  
The GAP activity of Plexin-B1 towards R-Ras induces neurite retraction and inhibits 
extracellular matrix-mediated cell migration in response to Sema4D, and functions 
independently of the modulation of Rho by Plexin-B1 (Oinuma et al. 2004; Oinuma et al. 
2006).   Plexin-B1 has also been shown to be a GAP for M-Ras in COS-7 cells and neurons 
(Saito et al. 2009).  The interactions between Plexin-B1 and R- and M-Ras affect the 
downstream signaling of R and M-Ras, including suppressing phosphatidylinositol-3-OH 
kinase [PI(3)K] signaling and activation of phosphatase and tensin homolog (PTEN) 
(Oinuma et al. 2006; Saito et al. 2009; Oinuma et al. 2010).  PI(3)K and PTEN are major 
regulators of PIP3, a key modulator of many cell processes including cell growth, migration, 
and survival that is often implicated in cancer and autoimmunity (Zhang et al.; Patel et al. 
2005).   
 
1.6D. Plexin-B1 and c-Met 
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Plexin-B1 is tyrosine phosphorylated within minutes of binding to Sema4D in porcine 
endothelial cells (Basile et al. 2005).  This phosphorylation of Plexin-B1 is required for 
activation of RhoA by Plexin-B1 and is meditated by epidermal growth factor receptor B-2 
(ErbB-2, also known as Human Epidermal growth factor Receptor 2 [HER2] in humans and 
neu in rodents) and N-Methyl-N'-nitro-N-nitroso-guanidine HOS Tranforming gene (c-Met) 
(Swiercz et al. 2002; Swiercz et al. 2004; Swiercz et al. 2008; Swiercz et al. 2009).  ErB-2 is 
a member of the family of epidermal growth factor receptor tyrosine kinases.  c-Met, also 
called hepatocyte growth factor receptor (HGFR), is a member of the scatter factor receptor 
family.  c-Met associates in a complex with Plexin-B1 in a ligand independent manor and is 
itself phosphorylated by ligand binding to Plexin-B1 (Giordano et al. 2002).  This co-
stimulation leads to the ability of cells to migrate towards Sema4D and to invasive growth in 
liver progenitor cells (Artigiani et al. 2003).  The interaction of c-Met and Plexin-B1 requires 
the extracellular domain of both proteins (Giordano et al. 2002).  The interaction between 
plexin and c-Met is mediated exclusively by the B family plexins and not other plexins 
(Conrotto et al. 2004).  Surprisingly in metastatic melanoma cells Plexin-B1 is diminished 
compared to benign melanomas, and expression of Plexin-B1 suppresses activation of c-Met 
and migration in response to hepatocytic growth factor (Stevens et al. 2010).   However 
Plexin-B1 did lead to the activation of Akt in melanoma cells, suggesting that Plexin-B1 may 
function in both tumor suppression and progression (Stevens et al. 2010).  The 
phosphorylation of Plexin-B1 is not required for its ability to bind to Rac-GTP or function as 
an R-Ras GAP (Swiercz et al. 2009).  
 
1.6E.  Plexin-B1 Binds to PLCγ 
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Swiercz et al. has shown that Plexin-B1 binds to both 1-phosphatidylinositol-4,5-
biphosphate phosphodiesterase γ1 (PLCγ) and growth factor receptor bound protein 2 (Grb-
2) upon activation by Sema4D in an Erb-2 containing breast cell line  (Swiercz et al. 2009).  
This binding is not observed in the breast cell line MDA-MB-468, which does not express 
Erb-2 (Swiercz et al. 2009).  PLCγ1 binding to Plexin-B1 is dependent on the tyrosine 
phosphorylation of Plexin-B1 by Erb-2 to create a docking site for PLCγ (Swiercz et al. 
2009).  PLCγ binding to Plexin-B1 results in activation of PDZ-Rho GEF through the SH3 
domain of PLCγ and induction of migration towards Sema4D and growth cone collapse in 
hippocampal neurons (Swiercz et al. 2009).   In ErbB-2 deficient cells, migration towards 
Sema4D but not fetal bovine serum is abolished, suggesting that PLCγ1 is required for 
Sema4D specific migration but not all migration (Swiercz et al. 2009).  This pivotal research 
links the activation of Plexin-B1 by its ligand Sema4D to its function as an activator for 
PDZ-RhoGEF and subsequent activation of Rho through creation of a docking site for PLCγ 
via phosphorylation of Plexin-B1 by ErbB-2.  This data also demonstrates that the processes 
involved in the Rho activation signaling pathway are separate from Plexin-B1 Rac-GTP 
binding and Plexin-B1’s function as a RasGAP as these two processes are not affected by 
mutations to Plexin-B1 that render it unable to be tyrosine phosphorylated by Erb-B2 
(Swiercz et al. 2008; Swiercz et al. 2009).  Additionally, c-Met phosphorylates Plexin-B1 in 
a different location than ErbB-2, and thus c-Met induces different downstream effects than 
Erb-B2, including pro and anti-migratory effects (Swiercz et al. 2008; Swiercz et al. 2009). 
 
1.6F.  Summary Model of Plexin-B1 Signaling 
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 Plexin-B1 signaling is very complex (Fig. 1.3).  One way to simplify the 
diverse functions of Plexin-B1 is to separate the known signaling components that function 
independently from those that function in response to ligand.  Ligand independent functions 
of Plexin-B1 include binding to c-Met and RacGTP.  c-Met can be phosphorylated by either 
its ligand HGF or by Plexin-B1 binding to its ligand Sema4D (Giordano et al. 2002).  
However, recent studies have demonstrated that c-Met is not phosphorylated in response to 
Sema4D, and c-Met phosphorylation is suppressed by expression of Plexin-B1 in melanoma 
cells (Stevens et al. 2010).  Plexin-B1 has also been shown to interact with active, GTP 
bound Rac, leading to sequestration of Rac from its downstream effector PAK (Vikis et al. 
2002).  The interaction of Plexin-B1 and active Rac has been characterized structurally and is 
thought to change the Plexin-B1 structure so that it is no longer able to dimerize (Hota et al. 
2009; Tong et al. 2009).  It is possible that binding to Rac changes Plexin-B1 so that it is no 
longer able to be dimerized in response to ligand, and thus can not activate RhoA.  However, 
studies in Drosophila suggest that Plexin-B downregulates Rac while enhancing RhoA 
activity (Hu et al. 2001).   Rac binding to Plexin-B1 is greatly increased by Sema4D binding 
to Plexin-B1 (Vikis et al. 2000), suggesting crosstalk between the two signaling pathways. 
Upon binding its ligand Sema4D, Plexin-B1 activates Rho through binding of its PDZ 
domain to the PDZ domain of the RhoGEFs PDZ and LARG (Aurandt et al. 2002; Driessens 
et al. 2002).  PDZ and LARG increase the exchange of GDP to GTP on Rho, increasing the 
amount of the active, GTP-bound form of Rho in the cell.  Plexin-B1 also acts as a GAP for 
R-Ras in response to its ligand, Sema4D (Oinuma et al. 2004).  The Rho GTPase Rnd1 is 
required for Plexin-B1 to function as an R-RasGAP (Oinuma et al. 2004).  Plexin-B1, upon 
Sema4D activation, shuts down R-Ras activation that occurs in response to adhesion to 
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fibronectin, and this results in suppression of R-Ras mediated activation of PI(3)K, inhibition 
of adhesion dependant cell migration and growth cone collapse (Oinuma et al. 2006).  Plexin-
B1 mediates the suppression of PI(3)K pathway through dephosphorylation and activation of 
PTEN, which functions as a phosphatase for PIP3 and therefore downregulates PI(3)K/PIP3 
pathway signaling (Oinuma et al. 2010).  The upstream pathway of Plexin-B1 mediated 
downregulation of PTEN is unknown, but is thought to involve casein kinase 2 alpha 
(CK2α), which phosphorylates and inactivates PTEN and is downregulated by Sema4D 
(Oinuma et al. 2010).  Plexin-B1 also serves as a GAP for M-Ras, which leads to 
downregulation of ERK activity and reduced dendrite outgrowth in cortical neurons (Saito et 
al. 2009). 
 Another group found that Sema4D binding to Plexin-B1 upregulates PI(3)K, AKT,  
ERK and migration (Basile et al. 2005; Aurandt et al. 2006).  How is this possible?  These 
dual functions are thought to be mediated by the binding state of Plexin-B1 to the receptor 
tyrosine kinases c-Met and ErbB-2 (Swiercz et al. 2008).  Plexin-B1 is preferentially bound 
to c-Met, and under these conditions RhoA and resulting migration is inhibited (Swiercz et 
al. 2008).  Plexin-B1 can also be found in complex with and be phosphorylated with ErbB-2, 
and this mediates activation of RhoA and migration through creation of a PLCγ docking site 
on Plexin-B1 for RhoGEFs (Swiercz et al. 2008; Swiercz et al. 2009).  c-Met and ErbB-2 are 
found alone or together in some cell types, and control of Plexin-B1 through these two 
receptor tyrosine kinases may be mediated by expression of c-Met and ErbB-2 or competitive 
binding.  Additionally, the Rho-GTPase p190 associates transiently with Plexin-B1 upon 
ligand stimulation and downregulates Rho (Barberis et al. 2005). 
 21 
 How the activity of Plexin-B1 as an R-RasGAP, binding partner to ErbB-2, c-Met, 
RacGTP, and p190 fits together as a signaling pathway has yet to be elucidated, and will 
likely require cell specific studies as well as studies of specific sites within cells to fully 
understand this complex signaling cascade.  The regulation of Plexin-B1 signaling by ligand 
binding and/or the presence of other plexins and semaphorins within the same cell remain 
pivotal questions critical to fully understanding Plexin-B1 biology. 
 
1.6G.  Plexin-B1 in the Immune System 
Plexin-B1 is found on immature bone marrow derived cDCs but not mature cDCs, 
and is absent on monocytes (Chabbert-de Ponnat et al. 2005).  In immature cDCs, soluble 
Sema4D, a ligand for Plexin-B1, inhibits migration, and this inhibition can be blocked by 
antibody against Plexin-B1 (Chabbert-de Ponnat et al. 2005).  Plexin-B1 is also expressed on 
bone marrow stromal cells, activated T cells, and follicular dendritic cells, and T cells and 
upon encounter with Sema4D on B cells leads to increased B cell proliferation (Granziero et 
al. 2003).  This limited exploration of Plexin-B1 in the immune system reflects a paucity of 
research in this area.   
 
1.7 Plexin-B2 Biology 
 Plexin-B2 is much less studied than the closely related Plexin-B1.  Studies of the 
phenotype of the Plxnb2-/- mouse in the nervous system reveal that Plexin-B2 is required for 
proper cell homing and neural tube closure (Friedel et al. 2007) The majority of data 
published for Plexin-B2 stems from Plexin-B1 focused articles in which Plexin-B2 was also 
included in limited experiments.  To date Plexin-B1 and Plexin-B2 share similarities in their 
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interactions with Rho family GTPases despite the fact that the intracellular tails of Plexin-B1 
and B2 are only 61% identical at the protein level (data not shown).  Plexin-B2 considered in 
the context of Plexin-B1 allows for immediate hypothesis and research direction (Fig. 1.4). 
 
1.7A. Plexin-B2 and RacGTPase 
 The Rho family small GTPase Rac has been implicated in many cell functions, 
including cell migration, adhesion, and morphology.  Similar to Plexin-B1, Plexin-B2 
overexpressed in Escherichia coli (E. coli) has been shown to bind to active, GTP bound 
form of Rac (Driessens et al. 2001).  Unlike Plexin-B1, in which many studies in mammalian 
cells have concluded that Plexin-B1 binds to Rac, the Plexin-B2 Rac interaction has not been 
studied in mammalian systems.  We can hypothesize that Plexin-B2 will also bind to Rac in 
mammalian cells, and will mediate functions similar to those found for Plexin-B1 including 
cell migration, adhesion, and morphology. 
 
1.7B.  Plexin-B2 and its Effects on Rho Activation 
Plexin-B2, similar to Plexin-B1, can associate with the Rho GEFs PDZ and LARG in 
yeast two hybrid screens and overexpression studies in HEK293 T cells (Driessens et al. 
2002; Perrot et al. 2002; Swiercz et al. 2002).  When Plexin-B2 is overexpressed in Swiss-
3T3 fibroblast cells and synthetically dimerized by replacement of extracellular Plexin-B2 
with TrkA, the receptor for nerve growth factor, Plexin-B2 upregulates active Rho through 
binding of the PDZ domain found in the cytoplasmic tail of Plexin-B2 to the PDZ domain of 
PDZ and LARG RhoGEFs (Perrot et al. 2002).  The RhoGEFs then exchange the inactive 
GDP-bound form of Rho to the active GTP-bound form of Rho (Perrot et al. 2002).  The 
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activation of Rho by dimerized Plexin-B2 in Swiss-3T3s induced stress fibers, which are 
characteristic of Rho activation (Perrot et al. 2002).  The binding of the B family plexins to 
PDZ-Rho and LARG is specific, as both Plexin-B1 and B2 were shown to not interact with 
the Rac-GEF Tiam 1, or the Rho-GEF p115RhoGEF, which does not contain the PDZ 
domain (Perrot et al. 2002).  Additionally, the activation of Rho requires dimerization of 
Plexin-B2, which is opposite of the interaction of Plexin-B1 and B2 with Rac (Perrot et al. 
2002). 
The observation that Plexin-B2 interacts with Rho through PDZ and LARG suggests 
that the Plexin-B2 modulation of Rho is identical to the modulation of Rho by Plexin-B1.  
The interaction with PDZ-Rho and LARG has also been shown in Drosophila Plexin-B, 
suggesting that this mechanism of control of Rho is highly conserved (Hu et al. 2001) and is 
likely an important function of B family plexins. 
 
1.7C.  Plexin-B2 and RasGAP Activity 
Plexin-B2 has not been directly studied for its effects as a RasGAP.  One study has 
shown that in COS-7 cells, when any of the B family plexins are expressed with Rnd1 and 
then stimulated by Sema4A, cells display growth cone collapse, a  phenotype associated with 
downregulation of R-Ras by Plexin-B1 (Yukawa et al. 2010).  This suggests that Plexin-B2 
may also function in this way.  Interestingly Sema4A in this overexpression assay binds to all 
B family plexins and induces very similar percentages of growth cone collapse among cells 
expressing either Plexin-B1, B2, or B3 (Yukawa et al. 2010), suggesting that these genes can 
be redundant in their function.   
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1.7D. Plexin-B2 and c-Met 
Plexin-B2, similar to Plexin-B1, binds to both c-Met and Ron, members of the scatter 
factor receptor family, although binding to Met is stronger (Conrotto et al. 2004).  Studies of 
Plexin-B1 with c-Met have demonstrated that this interaction regulates invasive ability in 
NIH3T3 cells in a ligand dependant manner (Conrotto et al. 2004).  The outcome of the 
interaction between Plexin-B2 with c-Met or Ron has not yet been studied. 
 
1.7E. Plexin-B2 Binds PLCγ 
Plexin-B2 has been shown to bind to PLCγ1 in the breast cancer cell line MCF-7 
upon binding to its ligand Sema4C, but not in the breast cancer cell line MDA-MB-468, 
which lacks Erb-2 expression (Swiercz et al. 2009).  Interestingly PLCγ1 is more expressed 
in the nervous system, and PLCγ2 in the immune, suggesting PLCγ expression may regulate 
nervous and immune cell differences in Rho activation downstream of Plexin-B2 (Swiercz et 
al. 2009).  The downstream consequences of Plexin-B2 interacting with PLCγ are unproven, 
but likely result in the upregulation of the RhoA pathway, similar to Plexin-B1. 
 
1.7F. Plexin-B2 in the Immune System 
Plexin-B2 has been identified as a gene that is upregulated in T-dependent but not T-
independent germinal centers.  However the biological function of the upregulation of 
Plexin-B2 in germinal centers has not yet been elucidated.  The research presented in this 
thesis explores the expression and function of Plexin-B2 in the immune system.  Our studies 
show that in the innate immune system Plexin-B2 is dynamically expressed on macrophages 
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and dendritic cells and plays a role in cell motility, modulation of RhoGEFs, and cytokine 
response. 
 
1.8 Conclusions 
 Plexins and semaphorins mediate many cell processes critical to the immune system 
including cell-cell contact, migration, and cytokine secretion.  The B family of plexins 
includes Plexin-B1, B2, and B3.  Plexin-B1 has been linked to regulation of the above 
processes through regulation of the actin cytoskeleton and its modulators, the Rho family of 
GTPases.  The data presented here demonstrate the role of another B family member, Plexin-
B2, in the immune system.  Plexin-B2 is found on macrophages and dendritic cells and 
affects the Rho family of  GTPases and cell motility. 
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Figure 1.1 
 27 
Figure 1.1:  Rho family GTPases are controlled by GAPs and GEFs. 
Rho family are intrinsic GTPases that modulate between GTP bound, active states and GDP 
bound inactive states to control downstream activities, the majority of which involve 
regulation of the actin cytoskeleton.  The binding state of Rho proteins are modulated by 
GEFs, which exchange GDP for GTP and turn the protein “on”, and GAPs, which accelerate 
the intrinsic GTPase capability of Rho family proteins and switch them to an inactive, GDP-
bound “off” state. 
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Figure 1.2 
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Figure 1.2:  Structure of the B family plexins. 
Plexin-B1, Plexin-B2, and Plexin-B3 contain a conserved, 500 amino acid extracellular 
domain, and three extracellular MRS domains that are common to all plexins.  Plexin-B1 and 
B2 are distinct from other plexins in containing furin-like cleavage sites, which may mediate 
extracellular cleavage and release of a soluble form of Plexin-B1 and Plexin-B2.  
Intracellularly, Plexin-B1-B3 contain a Rac/Ras binding domain that is flanked by two SP 
domains, which contain phosphorylation sites.  Plexin-B1 and B2 contain an intracellular 
PDZ domain that can dimerize with PDZ domains of RhoGEFs and facilitate the 
upregulation of Rho.  Figures were adapted from Tamagnone et al. (Tamagnone et al. 1999) 
and data from the National Center for Biotechnology Information (NCBI).  
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Figure 1.3 
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Figure 1.3:  Plexin-B1 regulates the Rho family of GTPases.  
Ligand independent functions of Plexin-B1: Plexin-B1 binds to c-Met.  c-Met can be 
phosphorylated by either binding to its ligand HGF or by Plexin-B1 binding to its ligand 
Sema4D (Giordano et al. 2002).  Plexin-B1 has also been shown to interact with active, GTP 
bound Rac, leading to sequestration of Rac from its downstream effector PAK (Vikis et al. 
2002). 
 
Ligand dependent functions of Plexin-B1: Plexin-B1 acts as a GAP for R-Ras when Rnd1 is 
also in the Plexin-B1 complex (Oinuma et al. 2004).  The Plexin-B1 mediated suppression of 
R-Ras induces inhibition of cell migration and suppression of PI(3)K pathway via activation 
of PTEN, resulting in inhibition of PIP3 and axonal growth cone collapse (Oinuma et al. 
2006; Oinuma et al. 2010).  Plexin-B1 also serves as a GAP for M-Ras, which leads to 
downregulation of ERK activity and reduced migration and dendrite outgrowth in cortical 
neurons (Saito et al. 2009).  This pathway operates when Plexin-B1 is bound to c-Met, and 
this binding partner is preferred over an alternative partner, ErbB-2.  When Plexin-B1 is in 
complex with ErbB-2 the PI(3)K pathway is upregulated (Basile et al. 2005; Aurandt et al. 
2006).  Plexin-B1 phosphorylation by ErbB-2 mediates activation of RhoA and migration 
through creation of a PLCγ docking site on Plexin-B1 for RhoGEFs (Swiercz et al. 2008; 
Swiercz et al. 2009).  Plexin-B1 activates Rho through binding of its PDZ domain to the PDZ 
domain of the RhoGEFs PDZ and LARG, leading to upregulated Rho, PI3K, AKT, ERK and 
migration (Driessens et al. 2002; Basile et al. 2005; Aurandt et al. 2006).  The Plexin-B1 
mediated activation of Rho can be downregulated by p190 (Barberis et al. 2005). 
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Figure 1.4 
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Figure 1.4:  Plexin-B2 regulates the Rho family of GTPases.  
Ligand independent functions of Plexin-B2:  Plexin-B2 binds to c-Met (Conrotto et al. 2005).  
Plexin-B2 binds to active, GTP bound Rac (Driessens et al. 2001). 
 
Ligand dependent functions of Plexin-B2:  Plexin-B2, when synthetically dimerized by 
replacement of its extracellular domain with a known receptor, activates Rho through binding 
of its PDZ domain to the PDZ domain of the RhoGEFs PDZ and LARG (Perrot et al. 2002).  
PDZ and Rho facilitate the activation of Rho by facilitating the exchanging GTP for GDP.  
Plexin-B2 has been shown to bind to PLCγ upon binding to its ligand Sema4C, and possibly 
interacts with ErbB-2, as the phosphorylation of Plexin-B1 by ErbB-2 creates the docking 
site for PLCγ (Swiercz et al. 2009). 
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ABSTRACT 
Plexins are cell surface receptors widely studied in the nervous system, where they mediate 
migration and morphogenesis though the Rho family of small GTPases.   More recently 
plexins have been implicated immune processes including cell-cell interaction, immune 
activation, migration, and cytokine production.  Plexin-B2 facilitates ligand induced cell 
guidance and migration in the nervous system and induces cytoskeletal changes in 
overexpression assays through RhoGTPase, but its function in the immune system is 
unknown.  This report shows that Plexin-B2 is highly expressed on cells of the innate 
immune system, including macrophages, conventional dendritic cells, and plasmacytoid 
dendritic cell.  However it does not have detectable effects on the production of 
proinflammatory cytokines, phagocytosis of a variety of targets, or directional migration 
towards chemoattractants.  Instead, Plxnb2-/- macrophages have greater cellular motility than 
wild type in the unstimulated state that is accompanied by more active, GTP-bound Rac and 
Cdc42.   Studies have shown that B family plexins bind to only active Rac.  The closely 
related B family member Plexin-B1 sequesters Rac from downstream signaling.  These data 
presented here show that Plexin-B2 functions in macrophages as a negative regulator of Rac 
and Cdc42 and as a negative regulator of cell motility. 
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INTRODUCTION 
The plexins are a family of nine transmembrane proteins that are grouped by 
homology into four subfamilies: A, B, C, and D (Tamagnone et al. 1999).  All family 
members share an extracellular semaphorin domain and an intracellular plexin domain-
containing tail that can mediate intracellular signaling.  The plexins were originally identified 
in the nervous system (Ohta et al. 1992; Ohta et al. 1995), where they have been found to 
mediate diverse cell processes including axon guidance, neurogenesis, cell migration, cell 
proliferation and death.  Plexins have also been found to function in other body systems 
including the reproductive, circulatory, endocrine, urinary, digestive, and immune system 
(reviewed in Kruger et al. 2005; O'Connor et al. 2008; Serini et al. 2009).  Similar to other 
plexins, the B family of plexins were originally found in the nervous system (Tamagnone et 
al. 1999), and were later identified in the circulatory, endocrine, reproductive, urinary, 
digestive, respiratory, and immune systems (Regev et al. 2005; Harduf et al. 2007; Gomez 
Roman et al. 2008; Harduf et al. 2009; Li et al. 2009; Okuno et al. 2009; Pan et al. 2009; 
Stevens et al. 2010; Zielonka et al. 2010).   The B plexin family is distinct from the A, C, and 
D plexins in the domains found in the intracellular tail.  Two of the B family members, 
Plexin-B1 and Plexin-B2, contain an intracellular domain with a PDZ motif [post synaptic 
density protein (PSD95), Drosophila disc large tumor suppressor (DlgA), and zonula 
occludens-1 protein (zo-1)] (Aurandt et al. 2002; Driessens et al. 2002; Hirotani et al. 2002; 
Perrot et al. 2002; Swiercz et al. 2002; Basile et al. 2004).   
In contrast to a paucity of studies on Plexin-B2, Plexin-B1 has been found in the 
immune system where it mediates processes similar to its function in the nervous system.  
Plexin-B1 is required for the optimal migration of monocytes and dendritic cells and 
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proliferation and survival of B cells (Granziero et al. 2003; Chabbert-de Ponnat et al. 2005).  
The mechanisms mediating these effects of Plexin-B1 in the immune system are unknown, 
but in other cell types the phenotypic effects of Plexin-B1 have been attributed to its role as a 
regulator of the Rho family of GTPases (Driessens et al. 2001; Aurandt et al. 2002; Driessens 
et al. 2002; Swiercz et al. 2002; Oinuma et al. 2004; Saito et al. 2009).  The Rho family of 
GTPases functions to regulate actin dynamics (Etienne-Manneville et al. 2002; Mulloy et al. 
2010).  Plexin-B1 has been shown to regulate Rho upon stimulation by binding to PDZ-Rho 
and LARGE (Driessens et al. 2001; Aurandt et al. 2002; Driessens et al. 2002; Swiercz et al. 
2002).   Plexin-B1, as well as Drosophila Plexin-B, have been shown to bind directly to the 
active GTP-bound form of the GTPase Rac but not the inactive, GDP bound form (Vikis et 
al. 2000; Driessens et al. 2001; Hu et al. 2001).  The downstream consequences of B family 
plexins binding to active Rac are not completely understood.  In overexpression studies 
performed in HEK293 cells, Plexin-B1- Rac-GTP binding has been shown to sequester 
active Rac from its downstream effector p-21-activated kinase (PAK), which leads to 
increased cell surface expression of Plexin-B1 (Vikis et al. 2000).  In Drosophila neurons, 
which have only one B family plexin, Plexin B binds to and down regulates Rac through an 
unknown mechanism (Hu et al. 2001).   
Plexin-B2, the focus of our study, is much less studied than Plexin-B1.  In 
overexpression studies Plexin-B2 has been found to regulate the GTPase Rho (Perrot et al. 
2002).  When Plexin-B2 is synthetically stimulated by replacement of its extracellular 
domain, the intracellular PDZ domain of Plexin-B2 binds to the PDZ domain of the 
RhoGEFs (guanine nucleotide exchange factors) PDZ-RhoGEF and LARGE (leukemia 
associated RhoGEF), leading to the activation of Rho and the formation of stress fibers in 
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fibroblast (Perrot et al. 2002).  Studies of Plexin-B2 in the mouse nervous system have 
demonstrated that Plexin-B2 is required for normal development during embryogenesis.  
Plxnb2-/- embryo brains have defects in cortical patterning and in cell guidance of several cell 
types, resulting in neural tube closure defects and exencephaly (Friedel et al. 2007; 
Hirschberg et al. 2010).  In the immune system, the function of Plexin-B2 has not been 
delineated, although Plexin-B2 has been identified on B cells as a marker of T cell dependent 
germinal center formation and on an undefined population of CD11b+ cells in the mouse liver 
(Yu et al. 2008; Zielonka et al. 2010).   The function of Plexin-B2 on these cells types has not 
been reported. 
This report shows that Plexin-B2 is most highly expressed by macrophages, 
conventional dendritic cells (cDC), and plasmacytoid dendritic cells (pDCs) and sought to 
determine the function of Plexin-B2 on these cells.  To explore the effects Plexin-B2 on the 
immune system, we created fetal liver chimeric mice to reconstitute the immune system of 
wild type mice with Plxnb2-/- cells because the Plxnb2-/- mice do not survive post-partum.  
Reconstitution of the immune system with Plxnb2-/- cells has similar efficiency as 
reconstitution with wild type cells providing a feasible system for this study.  The results 
show that Plxnb2-/- macrophages are not defective in their ability to secrete the inflammatory 
cytokines TNFα or IL-6, undergo phagocytosis of fluorescent beads, bacteria, or antibody 
bound T cells, or migrate towards chemokines CXCL12 and colony stimulating factor (CSF).  
However, Plxnb2-/- macrophages show a significant increase in cell mobility compared to 
wild type in steady state.  Additionally Plxnb2-/- cells have higher levels of the active forms 
of the small Rho GTPases Cdc42 and Rac.  These data show that Plexin-B2 is 
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transmembrane negative regulator of Rac and Cdc42 and modulates cell velocity in 
macrophages. 
 
RESULTS 
Plexin-B2 is expressed in the immune system. 
We and others have previously shown that Plexin-A1 is found on dendritic cells in the 
mouse immune system and is required for optimal stimulation of T cells and for proper 
formation of T cell-dendritic cell conjugates by influencing actin polarization (Wong et al. 
2003; Eun et al. 2006; O'Connor et al. 2008; Takamatsu et al. 2010).  These results prompted 
us to ask if other plexins were expressed in the immune system.  In silico analysis of the 
BioGPS database (Wu et al. 2009) demonstrates that human and mouse Plexin-B2 is highly 
expressed on macrophages, cDCs, and pDCs, with much less to little found on B and T cells 
(Fig. 2.1A, B).  This expression pattern was analyzed in the mouse at the protein level by 
flow cytometry (Fig. 2.1C).  Plexin-B2 is highly expressed on B220+ PDCA-1+ pDCs and 
CD11c+ B220- cDCs in spleen and bone marrow.  Plexin-B2 is also expressed moderately on 
splenic macrophages and higher on F4/80+ macrophages.  In addition bone marrow F4/80+ 
cells show two populations based on Plexin-B2 expression.  Bone marrow-derived B220+ B 
cells also express a higher amount of Plexin-B2 than splenic B cells.  The low levels of B cell 
Plexin-B2 transcript detected by in silico studies (Fig. 2.1A, B) and the much higher protein 
expression (Fig. 2.1C) might reflect post-transcriptional control of Plexin-B2 in B cells.  
Very little Plexin-B2 was detected on TCR+CD4+ T cells, TCR+CD8+ T cells, NK1.1+ natural 
killer (NK) cells, or NK1.1+TCR+ NK T cells consistent with the in silico studies. 
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Reconstitution of the immune system with Plxnb2-/- cells is equivalent to wild type. 
Mice lacking Plexin-B2 (Plxnb2-/-) have been previously shown to have a severe 
phenotype, exhibiting defects in neural tube closure, cerebellar disorganization and 
misregulated granule cell proliferation (Deng et al. 2007; Friedel et al. 2007).  To study the 
immune system, it was necessary to perform fetal liver transplant from Plxnb2-/- donor 
backcrossed onto a C57BL/6 background for at least ten generations into C57BL/6 CD45.1+ 
recipients.  We and others have shown that plexins can affect cell proliferation and 
homeostasis (Deaglio et al. 2004; Kumanogoh et al. 2005; Hu et al. 2007; O'Connor et al. 
2008; Takamatsu et al. 2010; Takamatsu et al. 2010).  Therefore we studied the ability of 
Plxnb2-/- cells to reconstitute the mouse immune system.   In the spleen and bone marrow, the 
reconstituted percentage of B220+ CD11c- (cDC), CD11clow PDCA-1+ (pDC) and F4/80+ 
(macrophage) cells, which express high levels of Plexin-B2, are equivalent in recipients of 
wild type Plxnb2-/- fetal livers (Fig. 2.2A).  This also holds true for B220+ CD11c- (B), TCR+ 
CD4+, and TCR+ CD8+ T cell percentages in the spleen and bone marrow (Fig. 2.2A).  
Furthermore, the total percentage of reconstituting donor (CD45.2+) cells compared to 
recipient (CD45.1+) is comparable for recipients of either Plxnb2-/- or wild type cells (Fig. 
2.2B).  These data suggest that Plexin-B2 does not affect cell proliferation or reconstitution 
of the mouse immune system in the fetal liver engraftment system used for the rest of the 
study. 
 
Plexin-B2 does not affect cytokine response in macrophages. 
Plexins and their semaphorin receptors have been shown to modulate cytokine 
secretion.  Plexin-A1 is required for upregulation of IFNα after Toll-like Receptor (TLR) 
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stimulation (Watarai et al. 2008).  Blocking antibodies to Plexin-B1 have been shown to 
abrogate Sema4D-induced cytokine modulation (Chabbert-de Ponnat et al. 2005).  To 
determine if Plexin-B2 also contributes cytokine response after TLR signaling, the 
inflammatory cytokines TNF and IL-6 in cell supernatants of macrophages stimulated by the 
TLR ligands Poly(I:C) (polyinosinic-polycytidylic acid, TLR3), LPS (lipopolysaccharide, 
TLR4), and R837 (imidazoquinoline compound imiquimod, TLR7) were assessed (Fig.2.3A, 
B).  In response to TLR ligands, Plxnb2-/- and wild type macrophages secreted comparable 
levels of TNFα and IL-6, indicating that Plexin-B2 does not play a role in the production or 
release of cytokines measured in this study. 
 
Plexin-B2 negatively regulates cell motility. 
Plexin-B2 has been shown in the nervous system to mediate cell guidance, migration, 
and proliferation These data prompted us to examine if Plexin-B2 could contribute to cell 
movement in macrophages.  We compared the motility of Plxnb2-/- and wild type 
macrophages on glass bottom dishes using time-lapse microscopy.  Three independent 
movies of Plxnb2-/- and wild type cells show that the mean velocity of Plxnb2-/- macrophages 
is significantly higher than wild type (Fig. 2.4A, B).  We also stimulated macrophages with 
macrophage colony stimulating factor (M-CSF) and found that while wild type macrophage 
motility increased with stimulation, Plxnb2-/- macrophage motility remained constant. This 
indicates that Plexin-B2 serve as a motility brake in unstimulated cells, and does not affect 
motility in response to M-CSF stimulation.  
 We also explored the directional migration capacity of Plxnb2-/- macrophages in 
transwell assays.  Macrophages have been demonstrated to migrate towards the attractive 
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chemokines M-CSF and stromal cell-derived factor-1 (CXCL12) (Kheir et al. 2005; 
Campana et al. 2009).  The data show that migration of Plxnb2-/- macrophages to M-CSF and 
CXCL12is normal compared to wild type.  This suggesting that while Plexin-B2 negatively 
regulates cell motility in steady state to prevent motility when cells are unstimulated, it does 
not regulate directed migration towards M-CSF and CXCL12 in macrophages.  
  
Plexin-B2 Negatively Regulates Rac and Cdc42. 
Previous studies with overexpressed Plexin-B2 in Swiss 3T3 cells have shown that 
Plexin-B2 binds to the active, GTP-bound form of Rac and contains a Rac binding motif in 
its intracellular tail (Driessens et al. 2001).  Following the findings that Plexin-B2 affects cell 
velocity, we investigated if this regulation of motility could be related to Plexin-B2 
dependent regulation of Rac.  Rac and Cdc42 have been demonstrated to modulate cell 
migration and motility (Etienne-Manneville et al. 2002; Pankov et al. 2005; Heasman et al. 
2008).  The GTP binding state of Rac and Cdc42 was assessed using GST–PBD (glutathione 
S-transferase PAK1 p21-binding domain) beads to pull down activated Rac and Cdc42 from 
cell lysate followed by specific detection of each of the molecule by western blot (Sander et 
al. 1998; Arthur et al. 2001).  In the unstimulated steady state, Plxnb2-/- macrophages 
repeatedly had more GTP bound Rac and Cdc42 than wild type (Fig. 2.5A).  Following 
stimulation with M-CSF for ten minutes, wild type and Plxnb2-/- macrophages showed 
similar levels of active Rac and less Cdc42.  This suggests that Plexin-B2 is a negative 
regulator of Rac and Cdc42 in the unstimulated state but not in the stimulated state.  Studies 
with the closely related protein Plexin-B1 have shown that Plexin-B1 binding to Rac-GTP 
occurs in steady state (Driessens et al. 2001).  Our data shows that Plexin-B2 is similar to 
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Plexin-B1 in that its effect on Rac but additionally found that the former also regulates 
Cdc42.  We also examined the effect Plexin-B2 on the ERK (extracellular-signal-related-
kinase) pathway, as previous studies of Plexin-B1 have shown that ERK is phosphorylated 
downstream of Plexin-B1 (Fig. 2.5B) (Aurandt et al. 2006).  Phosphorylated ERK levels in 
Plxnb2-/- and wild type macrophages were equivalent in the steady state and in response to 
treatment with M-CSF.  These data represent the first evidence that the endogenous effect of 
Plexin-B2 in unstimulated cells is to serve as a brake for Rac and Cdc42 activation. 
 
Plexin-B2 does not affect macrophage phagocytosis. 
The Rho family of GTPases regulate the process of phagocytosis, in which actin 
dynamics facilitate the cellular processes of membrane extension, phagocytic cup formation 
and closure, and particle uptake (reviewed in Fenteany et al. 2004).  Rac and Cdc42 have 
been shown to mediate FcγR mediated phagocytosis in macrophages (Cox et al. 1997; Caron 
et al. 1998; Park et al. 2009).  Plexin-C1, in response to viral semaphorin, has been shown to 
downregulate phagocytosis (Ji et al. 2009). 
 To test whether the negative regulation of Rac and Cdc42 by Plexin-B2 in 
macrophages has an effect on phagocytosis we performed experiments to examine the uptake 
of GFP-E. coli, latex beads, and antibody coated thymocytes (Fig. 2.6A, B, C).  Plxnb2-/- or 
wild type macrophages were given either GFP-E. coli, fluorescent latex beads, or antibody 
coated thymocytes and assayed for cellular uptake using flow cytometry at different time 
points.  Both Plxnb2-/- and wild type macrophages were capable of phagocytosing all 
treatment groups.  However, the ability to phagocytose antibody coated thymocytes 
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repeatedly trended towards greater uptake of these thymocytes by Plxnb2-/- macrophages 
although this difference is not significant. 
  
DISCUSSION 
This is the first report to explore the expression of Plexin-B2 on macrophages, cDCs, 
and pDCs.  We found that Plexin-B2 is not expressed on resting B cells in the spleen, in 
agreement with previously reported expression of Plexin-B2 in B cells within T-dependent 
germinal centers (Yu et al. 2008).  By contrast, Plexin-B2 expression on T cells is consistent 
and it is not highly expressed in CD4+ or CD8+ splenic T cells or NK or NK T cells at the 
transcript and protein level.  In the BioGPS cDNA database (Wu et al. 2009), Plexin-B2 is 
most highly expressed in the macrophage, cDC and pDC in the immune system.  Our protein 
data confirms the database results.  Interestingly, the same database shows Plexin-B1 has no 
immune system cDNA expression above median, and Plexin-B3 is most highly expressed in 
mast cells (data not shown).  Other studies have demonstrated that Plexin-B1 is expressed in 
B cells, monocytes, and dendritic cells in humans (Granziero et al. 2003; Chabbert-de Ponnat 
et al. 2005).  This suggests that expression level of different B family plexins is cell type 
specific and may be a way of regulating the function of B family plexins. 
 The functional analyses indicate that Plxnb2-/- macrophages have higher steady state 
velocity than wild type macrophages by live cell microscopy, suggesting that Plexin-B2 is a 
negative regulator of cell velocity.  The data demonstrates that directional migration of both 
Plxnb2-/- and wild type macrophages in response to cytokines M-CSF or CXCL12 are 
equivalent, suggesting that stimulated, directional migration is not affected by Plexin-B2 
with these chemokines.  The majority of the studies of Plexin B family members have relied 
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on activation of the plexin receptor by its ligand or by synthetic dimerization.  Here we show 
that endogenous, unstimulated Plexin-B2 regulates macrophage velocity in steady state.  It is 
possible that Plexin-B2 may be dimerized in an autocrine fashion in our system by one of its 
reported ligands Sema4A, Sema4C, or Sema4D in steady state (Masuda et al. 2004; Deng et 
al. 2007; Yukawa et al. 2010; Zielonka et al. 2010).  Under the scenario, the semaphorin 
ligand could be secreted by macrophages, or could be provided by neighboring cells in the 
culture.  However, we are able to use a monoclonal antibody to stain for surface expression 
of Plexin-B2 indicating that either the anti-Plexin-B2 antibody binds to a portion of Plexin-
B2 that is not occupied by ligand binding or that Plexin B2 is not bound to its ligand in our 
experimental conditions.   
 To explore the mechanism of Plexin-B2 negative regulation of cell velocity, 
GTP pull down assays were carried out to determine the amount of active Rac and Cdc42.  
The data show that in the unstimulated steady state, Plxnb2-/- cells have higher levels of the 
GTP bound, active forms of Cdc42 and Rac.  Previous reports have shown that Plexin-B2 in 
its undimerized form binds to Rac-GTP in yeast and in bacterial overexpression studies 
(Driessens et al. 2001).  Our data suggests that similar to Plexin-B1, Plexin-B2 may bind to 
RacGTP and function to sequester Rac from it downstream effectors (Vikis et al. 2002).  In 
the absence of Plexin-B2, there is more active Rac, suggesting that Plexin-B2 might increase 
RacGAP (Rac GTPase accelerating protein) activity by serving as a RacGAP itself or recruits 
a RacGAP to the Plexin-B2 complex.  Structural and biochemical studies of Plexin-B1 have 
shown that Plexin-B1 does not function as a RacGAP, suggesting that the Plexin-B1 
modulation of Rac is through other mechanisms (Bouguet-Bonnet et al. 2008; Hota et al. 
2009).  The intracellular tails of Plexin-B1 and Plexin-B2 are similar (61% identical in their 
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amino acid sequence – data not shown) it is likely that Plexin-B2 also itself does not function 
as a RacGAP but instead mediates activity towards Rac through the modulation of other 
regulators in this pathway.  Interestingly Plexin-B1 has been shown in yeast to not interact 
with Cdc42, while our data indicate that Plexin-B1 does modulate Cdc42 activation.  This 
reveals a difference between Plexin-B1 and Plexin-B2, however species differences have to 
be taken into account for these differences.  We observe the effects of Plexin-B2 on Rac and 
Cdc42 only in an unbound state.  
 This study revealed several functions that are not regulated by Plexin-B1.  The 
reconstitution ratios of wild type or Plxnb2-/- fetal liver cells are similar in wild type 
recipients, and the percent of specific immune cell populations in the spleen and bone 
marrow reconstituted equivalently.  This includes cell types that express the highest levels of 
Plexin-B2: the cDC, pDC, and macrophage.  Numbers of macrophage cells derived from 
bone marrow cultures of Plxnb2-/- and wild type cells are equal, suggesting that Plexin-B2 
does not contribute to detectable differences in immune system ontogeny or proliferation in 
this study. 
 Antibody-mediated phagocytosis is a Cdc42 dependent mechanism.  Therefore we 
explored the phagocytic capacity of Plxnb2-/- macrophages compared to wild type.  However, 
the findings show that Plxnb2-/- macrophages are capable of phagocytosis of GFP-E. coli, 
latex beads, and antibody coated thymocytes.  Phagocytosis of GFP-E. coli and latex beads is 
similar for Plxnb2-/- and wild type macrophages.  However, there was a trend of increased 
phagocytosis of antibody-coated thymocytes by Plxnb2-/- macrophages.  Antibody-mediated 
phagocytosis has been shown to be dependant on Rac and Cdc42 (Caron et al. 1998), while 
bacteria bypass the need for activation of the small GTPases for cellular uptake (Gruenheid et 
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al. 2001).  It is possible that the over activation of Rac and Cdc42 in the absence of Plexin-
B2 leads to a modest upregulation of antibody-mediated phagocytosis, but not phagocytosis 
of E. coli and latex beads.   
Previous reports have shown that Plexin-B1 and other plexins can influence cytokine 
production in monocytic cells (Holmes et al. 2002; Chabbert-de Ponnat et al. 2005).  
However this study shows that TNFα and IL-6 production and secretion in response to TLR 
ligands is similar between wild type and Plxnb2-/- macrophages.  Thus in our system cytokine 
secretion is not affected by the absence of Plexin-B2 signaling.  It is possible that 
dimerization of Plexin-B2 or stimulation by its ligand could show that Plexin-B2 has a role in 
macrophage cytokine secretion and should be addressed in future studies. 
In summary, this study shows that Plexin-B2 is highly expressed in the immune 
system on cells of monocytic-myeloid lineage, including the cDC, pDC, and macrophage. 
Plexin-B2 has been shown previously to bind to only to the activated form of Rac, but the 
physiological consequence of Plexin-B2 Rac-GTP binding is unknown.   We show that ex-
vivo Plxnb2-/- macrophages have higher levels of activated Rac and Cdc42 and increased cell 
velocity in steady state.  Our data suggest that the function of Plexin-B2 in steady state is to 
negatively regulate Rac and Cdc42 and to maintain a brake on cell motility in unstimulated 
cells. 
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MATERIALS AND METHODS 
Mice 
C57BL/6 (CD45.2) and congenic C57BL/6 (CD45.1) mice were purchased from National 
Cancer Institute (Boston, MA).  Plxnb2-/- mice were provided by Dr. Marc Tessier-Lavigne 
(Friedel et al. 2007) (Stanford) and were backcrossed with C57BL/6 mice at least 10 
generations at the University of North Carolina Chapel Hill.  Mice were used at six to eight 
weeks of age and were housed in a pathogen-free barrier facility at the University of North 
Carolina Chapel Hill.  All animal procedures were approved by the Institutional Animal Care 
and Use Committee of the University of North Carolina at Chapel Hill and were performed 
in compliance with the National Institutes of Health Guide for the Care and Use of 
Laboratory Animals.  Plxnb2+/- mice were crossed to obtain Plxnb2-/- and wild type fetal 
livers from stage E14 pups.  Fetal liver cells were then injected intravenously into lethally 
irradiated C57BL/6 CD45.1 to reconstitute the immune system and analyzed 6-10 weeks post 
reconstitution (Godin et al. 2002). 
 
Cell culture 
Macrophages were generated by bone marrow culture in L929 media.  In brief, mouse femurs 
and tibias were removed from 6-8 week old mice, cleaned, and aspirated to remove bone 
marrow.  Cells were cultured in L929 for six days.  Macrophages were harvested and 
replated in complete DMEM media [DMEM, 10% heat inactivated fetal bovine serum, non-
essential amino acids, L-glutamine, sodium pyruvate, and penicillin/streptomycin (P/S)], and 
rested overnight before experiments. 
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Reagents 
Poly(I:C), Ultrapure LPS, and Imiquimod (R837) were from InvivoGen.  M-CSF is from 
R&D Systems (Minneapolis, MN).  Antibodies for western blotting included Rac1 (C-14; sc-
217), Cdc42 (B-8; sc-8401), phospho-ERK1/2 (Thr202/Thr204) (197G2; 4377) from Santa 
Cruz Biotechnology (Santa Cruz, CA) and GAPDH (MAB374) from Millipore (Billerica, 
MA).  Secondary goat α mouse-HRP (horse radish peroxidase) and goat α rabbit-HRP 
antibodies are from Santa Cruz Biotechnology (Santa Cruz, CA).  Beads for assays of GTP-
bound Rac1 and Cdc42 glutathione-sepharose (GST) bead conjugated with Pak1 binding 
domain (Rac1 and Cdc42) were kindly provided by Dr. Keith Burridge  (University of North 
Carolina, Chapel Hill). 
 
Flow cytometry 
Antibodies used for flow cytometry included: B220 (RA3-6B2), CD45.2 (104), CD45.1 
(A20), CD4 (L3T4), CD8 (Ly-2), TCR (H57-597), CD11b (M1/70), CD11c (N418), NK1.1 
(NKR-P1C) PDCA-1 (BST2, CD317) and Plexin-B2 (3E7) from eBioscience (San Diego, 
CA).  Single cell suspensions of spleen and bone marrow were lysed in ACT to remove red 
blood cells, washed and resuspended in FACS buffer (1X PBS and 2% FBS) at 1x10 6 cells 
per well and stained with antibody combinations. All experiments were performed on a 
FACSCalibur (BD Biosciences, Franklin Lakes, NJ) or Cyan (Dako, Carpinteria, CA) and 
analyzed with FlowJo software (Tree Star, Ashland, OR). 
 
Live Cell Microscopy 
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1x104 cells were plated on glass bottom dishes (MatTek Ashland, MA P35G-1.5-10-C).  
Cells were imaged on a Nikon Biostation (Belmont, CA) with a 20X objective.  Cell velocity 
was analyzed using manual tracking in ImageJ (Abramoff 2004).  Images were collected 
every 5 minutes for a total time of 2.5 hours for unstimulated cells or following treatment 
with 50ng/ml M-CSF.  For each treatment three separate movies were filmed and 45 cells 
scored for velocity.  n=3 mice per group. 
 
Detection of GTP-bound Rac1, Cdc42, and pERK 
Cells were plated at 2x10 6 cells per well in six well plates and treated with 50ng/ml M-CSF or 
media for the indicated times.  Assays for GTP-bound Rac1 and Cdc42 were performed as 
described (Noren et al. 2003).  Cells were lysed and precipitated using GST-PBD beads for 
Rac and Cdc42.  Bead bound proteins and cell lysate were resolved on a NuPAGE (Invitrogen 
Carlsbad, CA) gel and were transferred onto nitrocellulose membranes.  Membranes were 
blocked with 10% milk and probed with primary antibodies against Rac1 and Cdc42 followed 
by appropriate secondary HRP conjugated antibody for detection.  For detection of pERK cells 
were plated as above, treated with 50ng/ml M-CSF for the indicated times, lysed and resolved 
on a NuPage (Invitrogen Carlsbad, CA) gel. 
 
Phagocytosis 
Macrophages were plated at 1x105 cells per well in a 96 well non-tissue culture treated plate 
in 100ul of macrophage media without antibiotics.  Cells were rested overnight and then 
treated with 1x107 GFP E. coli (green fluorescent protein expressing Eshericia coli kindly 
provided by Dr. Glenn Matoshima, University of North Carolina Chapel Hill), 1x107 
fluorescent latex beads (Invitrogen F13080, Carlsbad, CA), or 1x106 CFSE 
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(carboxyfluorescein diacetate succinimidyl ester, Invitrogen, Carlsbad, CA) labeled, antibody 
labeled (CD45.2, mouse IgG2a) thymocytes as previously described (Scott et al. 2001).  
Cells were washed with media, extracellular fluorescence quenched with 0.2% Trypan Blue 
(Sigma T8154, St. Louis, MO), fixed in 0.1% EM-grade formaldehyde and analyzed by flow 
cytometry for percent of fluorescent positive cells. 
 
ELISA 
Macrophages were plated at 2x105 cells per well in a 96 well plate and stimulated overnight.  
Cell supernatants were quantified using the ELISA kits for mouse TNF-α (555268) or IL-6 
(555240) (BD Biosciences San Jose, CA).   
 
Statistical analysis 
Statistical significance was determined with two-tailed Student’s t test.  All p values less than 
0.05 were considered significant.  
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Figure 2.1 
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Figure 2.1.  Plexin-B2 is expressed in the human and mouse immune system.   
A) cDNA expression level of Plxnb2 in mouse immune cells from BioGPS database (Wu et 
al. 2009).  B) cDNA expression level of Plxnb2 in human immune cells.  C) Plexin-B2 
protein expression by flow cytometry of ex-vivo mouse spleen and bone marrow cells.  pDCs 
were gated on B220+ PDCA-1+ cells.  cDCs were gated on CD11c+ B220- cells.  
Macrophages were gated on F4/80+ CD11c- cells.  B cells were gated on B220+ cells.  T cells 
were gated on TCR+ cells.  NK cells were gated on NK1.1+ TCR- cells, and NK T cells on 
NK1.1+TCR+ cells.  Wild type fetal liver reconstituted mice are indicated by unfilled 
histogram and Plxnb2-/- reconstituted mouse by filled histogram.  Results are representative 
of at least four experiments, n=8 per group. 
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Figure 2.2 
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Figure 2.2.  Immune system reconstitution with Plxnb2-/- fetal livers is similar to wild 
type.   
Flow cytometry of reconstitution of congenic CD45.1+ mice with wild type and Plxnb2-/- 
fetal livers (CD45.2+) in the splenic and bone marrow compartments six weeks post 
transplant.  A) cDCs are designated as B220-/CD11c+ cells, pDCs as CD11c+ B220+, and B 
cells as B220+ CD11c-. pDCs were further defined as CD11clow and PDCA-1+.  Macrophages 
were defined as F4/80+ cells. T cells were first gated on TCR+ cells, and then divided into 
subpopulations by the CD4+ and CD8+ markers.  NK cells were defined as NK1.1 +/CD4- 
and NKT cells as NK1.1+CD4+. B) Total donor reconstitution in the spleen and bone 
marrow were similar between wild type and Plxnb2-/- mice. CD45.2 marked the donor, 
Ly5.1+ cells.  CD45.1 marked the residual host, Ly5.2+ cells.  Figures are representative plots 
of four separate experiments.  n=5 mice per group. 
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Figure 2.3 
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Figure 2.3:  Plexin-B2 does not affect cytokine secretion.   
Wild type and Plxnb2-/- macrophages were incubated for 16 hours with TLR ligands 
Poly(I:C) (10 ug/ml), LPS (1ug/ml) , and R837 (4 ug/ml).  Supernatants were collected at the 
16 hour time point and assessed for secretion of A) TNF and B) IL-6 by ELISA.  Graphs are 
representative of three independent experiments, n=3 mice per group.   
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Figure 2.4 
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Figure 2.4.  Plxnb2-/- cells have higher velocity than wild type macrophages.   
A) Representative cell movement tracks over a 2.5 hour time period on untreated wild type or 
Plxnb2-/- macrophages.  B) Combined velocity scores of wild type and Plxnb2-/- bone marrow 
macrophages in untreated or treated (50ng/ml M-CSF) groups.  Cell velocity was scored in 
45 cells per group per experiment.  The experiment was repeated three separate times using 
cells from different mice in each experiment.  C) Macrophage transwell migration towards 
CSF and CXCL12.  Cells were placed in the upper chamber and chemokines in the lower 
chamber of migration plates and allowed to migrate for four hours.  Cells were quantified and 
normalized to a standard curve of each genotype.  Graphs are representative of at least three 
independent experiments.  n= 4 mice per group. 
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Figure 2.5 
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Figure 2.5:  Plexin-B2 inhibits active Rac and Cdc42.   
A) WT and Plxnb2-/- macrophages were plated and rested overnight and assessed for 
RacGTP, Cdc42GTP, total Rac and total Cdc42 using a GST-PBD pulldown assay followed 
by western blot. B) Western blot of ERK activation as assessed by phospho-ERK level in 
untreated cells, as well as in response to 2 and 5 minutes of treatment with CSF (50 ng/ml) 
and 20 minutes of treatment with LPS (1 ug/ml).  Total protein level was determined by 
western blot of GAPDH.  Results are representative of four separate experiments.  n= 4 mice 
per group. 
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Figure 2.6 
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Figure 2.6:  Plexin-B2 does not significantly affect phagocytosis.  
A) Wild type and Plxnb2-/- bone marrow derived macrophages were incubated with GFP-E. 
coli, latex beads, or opsonized thymocytes (1:10 ratio E.coli, bead, or T cells: macrophage) 
for 30, 60, or 90 minutes.  Uptake was measured by fluorescence and flow cytometry.  
Graphs are representative or four independent experiments. n=5 mice per group. 
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ABSTRACT 
The plexin gene family is implicated in cellular movement and cell-cell communication 
during the course of the immune response.  In this study, we characterize the expression and 
function of Plexin-B2 and Plexin-D1 in the immune system.  We show that Plexin-B2 and 
Plexin-D1 are differentially expressed in dendritic cell (DC) populations.  Expression of 
Plexin-B2 and Plexin-D1 is modulated upon activation of DCs by TLR ligands, TNFα, and 
anti-CD40.  Absence of Plexin-B2 and Plexin-D1 in DCs does not affect the ability of these 
cells to upregulate costimulatory molecules or the ability of these cells to activate antigen 
specific T cells.  Additionally, Plexin-B2 and Plexin-D1 are dispensable for chemokine-
directed in-vitro migration of DCs towards CXCL12 and CCL19.  However, absence of 
Plexin-B2 or Plexin-D1 on DCs leads to constitutive expression of IL-12/IL-23p40.  Plexin-
B2 and Plexin-D1 are negative regulators of IL-12/IL-23p40 signaling.  This suggests that 
both Plexin-B2 and Plexin-D1 may play a role in dendritic cells in cytokine and T cell 
response. 
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INTRODUCTION  
Semaphorins and plexins were initially identified as key molecules in axon guidance 
during neuronal development (Kolodkin et al. 1993; Winberg et al. 1998).  Semaphorins are 
classified into three different groups based on their origin and structural homology; 
invertebrate, vertebrate and viral semaphorins (Mizui et al. 2009).  Plexin receptors are 
divided into two large groups, invertebrate and vertebrate, and further subdivided into four 
different families, A-D (Takamatsu et al. 2010).  Although plexins are considered receptors 
for the semaphorin ligands, this view has been revised as semaphorins are shown to also 
mediate signal transduction (Tamagnone et al. 1999; Castellani et al. 2002; Kruger et al. 
2005; Yazdani et al. 2006).  The interactions between semaphorins and plexins are 
promiscuous.  Semaphorins can interact with multiple plexins on a single cell type or across 
multiple cell types and vice versa (Takamatsu et al. 2010).  Plexins and semaphorins control 
cell movement and migration and have been implicated in neural cell function, vasculature 
formation, and organ development (van der Zwaag et al. 2002; Gu et al. 2005; Choi et al. 
2008; Sakurai et al. 2010).  
Recent work has implicated plexins and semaphorins in the immune system 
(Granziero et al. 2003; Wong et al. 2003; Walzer et al. 2005; Yamamoto et al. 2008).  
Several plexins and semaphorins are expressed by naïve and activated immune cells.  Plexin-
D1 and Semaphorin-3E are expressed in the thymus (Choi et al. 2008).  Plexin-A1 and 
Semaphorin-6D are expressed on DCs and T cells (Wong et al. 2003; O'Connor et al. 2008).  
Semaphorin-4A is expressed by Th1 polarized T cells and DCs (Kumanogoh et al. 2002).  
Semaphorin-4D is expressed by T cells, DCs, and activated B cells (Delaire et al. 1998; 
Kumanogoh et al. 2000; Shi et al. 2000; Kumanogoh et al. 2002; Granziero et al. 2003; 
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Kumanogoh et al. 2005).  Plexin-A4 is expressed by T cells, B cells and DCs (Yamamoto et 
al. 2008).  Plexin-C1 is expressed by DCs (Walzer et al. 2005).  The wide distribution of 
plexins and semaphorins across immune system cells and environments suggest that they 
function in immune system development and response. 
The function of plexins and semaphorins on DCs has not yet been fully characterized.  
Plexin-A1 expression on DCs is required for proper T-cell activation and proliferation (Wong 
et al. 2003; Takamatsu et al. 2010).  Semaphorin-6D, a known ligand for Plexin-A1, is 
expressed on activated T cells and is required for late-phase T cell proliferation (O'Connor et 
al. 2008).  Mice deficient in Plexin-A4 develop exacerbated MOG-induced experimental 
autoimmune encephalomyelitis (EAE) (Yamamoto et al. 2008).  Semaphorin-4D maintains 
B-cell homeostasis and facilitates humoral immune responses (Shi et al. 2000).  Plexin and 
semaphorin function on DCs demonstrate their importance in the immune response. 
To date, Plexin-D1 and Plexin-B2 research in the immune system has been limited.  
In other systems Plexin-D1 partners with two different semaphorin molecules: Semaphorin-
3E and Semaphorin-4A (Gu et al. 2005; Toyofuku et al. 2007).  Plexin-B2 has been found to 
have several semaphorin ligands including Semaphorin-3E, Semaphorin-4A, Semaphorin-
4C, and Semaphorin-4D (Masuda et al. 2004; Lamont et al. 2009; Yukawa et al. 2010; 
Zielonka et al. 2010).  Plexin-D1 was recently shown to be expressed by double positive 
thymocytes and facilitate their migration from the cortex into the medulla (Choi et al. 2008).  
Plexin-B2 is expressed on T-dependent germinal center B cells but not T-independent 
germinal center B cells, though the physiological consequence of this increase in expression 
are unknown (Yu et al. 2008).  Studies of development in the model organism zebrafish have 
shown that Plexin-B2 and Plexin-D1 are antagonistic- Plexin-B2 deficiency results in 
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delayed migration of sprouting angioblast while Plexin-D1 deficiency results in early 
angioblast sprouting (Lamont et al. 2009).  These findings show that Plexin-B2 and Plexin-
D1 likley function in the same pathway but have differing roles.  The expression of both of 
these plexins is important for timing of cell homing. 
In this study, we report that Plexin-B2 and Plexin-D1 are differentially expressed in 
DCs.  To address the role of Plexin-B2 and Plexin-D1 in DC development and function we 
utilized Plxnd1-/- and Plxnb2-/- animals.  We used in-vitro and in-vivo approaches to examine 
the direct effect of Plexin-B2 and Plexin-D1 on DCs.  We found that DCs lacking Plexin-B2 
and Plexin-D1 were capable of inducing a normal T cell response in response to antigen.  We 
also found that both Plxnb2-/- and Plxnd1-/- DCs are capable of migrating towards 
chemokines and are present in the spleen in patterns comparable to wildtype.  Plxnb2-/- and 
Plxnd1-/- DCs are capable of secreting normal amounts of TNFα and IL-6.  However, both 
Plxnb2-/- and Plxnd1-/- DCs are hyper-responsive in their secretion of IL-12/ IL-23p40.  Our 
results show that in DCs, both Plexin-B2 and Plexin-D1 are differentially expressed and the 
absence of either does not impact T cell proliferation response, chemokine directed 
migration, and IL-6 and TNF secretion.  However, both Plexin-B2 and Plexin-D1 are 
negative regulators of IL-12/IL-23p40 response, demonstrating that they may function in 
DCs in the same pathway and that this pathway may be modulated by their differential 
expression. 
 
RESULTS 
Plexin-B2, Plexin-D1, and Semaphorin-3E Expression in Immune Cells 
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Expression patterns of individual plexins in the immune system during cell 
maturation or activation have been reported in the literature.  Plexin-B2 is expressed on B 
cells from T cell dependent germinal centers but not T independent germinal centers (Yu et 
al. 2008).  Plexin-D1 is expressed by thymocytes and further downregulated with T cell 
maturation (Choi et al. 2008).  We extended Plexin-B2 and Plexin-D1 expression studies to 
include another immune cell type, DCs.  DCs are required for T cell priming in the secondary 
lymphoid organs.  We observed Plexin-B2 and Plexin-D1 expression in sorted splenic 
myeloid DCs (mDCs) (CD11b+CD11c+) (Fig. 3.1A, B, and C).  Plexin-B2 is expressed at day 
6 of maturation of bone marrow derived DCs treated with GM-CSF and IL-4, then decreases 
mid-maturation at day 8, and then increases at maturation day 10 and treatment with TNFα 
and IL-6 (Figure 1A).  Plexin-B2 expression is not increased by treatment with toll-like 
receptor (TLR) ligands (P3C, TLR1/2), lipopolysaccharide (LPS, TLR4), or CpG (TLR9).  
Plexin-B2 is highly expressed by plasmacytoid DCs (CD11c+B220+mPDCA1+) (Fig. 3.1A, 
B).   
The expression pattern of Plexin-B2 is in contrast with the expression pattern of 
Plexin-D1, which increases throughout the maturation of bone marrow-derived DCs 
(BMDCs) and with treatment by TLR ligands P(3)C, LPS, and CpG (Fig. 3.1C).  Plexin-D1 
expression is not increased in response to treatment with TNFα or CD40L, and is not 
expressed on plasmacytoid DCs.  Both Plexin-B2 and Plexin-D1 are expressed on splenic ex-
vivo DCs (Fig. 3.1A, C). 
We confirmed the expression of Plexin-B2 throughout DC maturation at the protein 
level using a monoclonal antibody against Plexin-B2 (Fig. 3.1B).  In conventional DCs that 
are produced with GM-CSF and IL-4, our data showed that expression of Plexin-B2 is 
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bimodal throughout maturation.  In plasmacytoid DCs that are matured with Flt3L Plexin-B2 
is highly expression throughout maturation.  These data support the differential cDNA 
expression pattern of Plexin-B2 (Fig. 3.1A). 
Studies have shown that the predominant Plexin-D1 partner in the immune system is 
Semaphorin-3E, although the specific cell type providing the ligand is unknown (Gu et al. 
2005; Choi et al. 2008).  These studies show that Semaphorin-3E is expressed in the thymic 
medulla where it creates a gradient that is responsible for migration of Plexin-D1 expressing 
thymocytes from the cortex into the medulla (Choi et al. 2008).  The immune system binding 
partner for Plexin-B2 is unknown.  However, in zebrafish angioblast, Semaphorin-3E is the 
ligand for Plexin-B2, and Plexin-D1 antagonizes the Plexin-B2/Semaphorin-3E pathway.  
Upon observing the opposing expression patterns of Plexin-B2 and Plexin-D1 in cDCs, we 
hypothesized that Semaphorin-3E may also be present on DCs.  We analyzed Semaphorin-3E 
expression in a number of immune cells (Figure 1D).  Our data show that Semaphorin-3E is 
minimally detected in naïve and activated T and B cell populations.  However, Semaphorin-
3E is highly expressed on Th2 skewed T cells and splenic cDCs.  The expression pattern of 
Semaphorin-3E suggests that partnering of this protein with Plexin-B2 and Plexin-D1 during 
the course of an immune response may be important for T cell activation.  
 
Plxnb2-/- and Plxnd1-/- DCs stimulate T cells similarly to wild type  
DCs are proficient antigen presenting cells required for proper T cell selection in the 
thymus and activation of naïve T cells in the periphery (Cella et al. 1997; Hanahan 1998).  
DCs take up antigen and present it to T cells in the context of MHC molecules (Hanahan 
1998).  Upon cognate antigen encounter, T cells proliferate, release a series of cytokines and 
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function as cytotoxic T-lymphocytes or helper T cells (Th) (Hanahan 1998).  To further 
define the role of Plexin-B2 and Plexin-D1 in DCs, we performed an in-vitro antigen 
presentation assay using transgenic T cells specific for ovalbumin (OVA), OTII T cells.  
Given that Plxnb2-/- and Plxnd1-/- mice die shortly after birth we created fetal liver chimeric 
mice to study Plexin-B2 and Plexin-D1 in the immune system.   Wild type congenic mice 
were reconstituted with hematopoietic cells from E14 fetal livers of Plxnb2-/- or Plxnd1-/- 
mice (Fig. 3.2).  
We first determined the ability of Plxnb2-/- and Plxnd1-/- DCs to take up OVA-protein.  
DCs were cultured for 2 hours in the presence of FITC-labeled OVA protein and the amount 
of OVA taken up by DCs was assessed by flow cytometry.  Plxnb2-/-, Plxnd1-/- and wild type 
DCs take up antigen equivalently as shown by the level of mean fluorescence intensity of the 
analyzed DCs (Fig. 3.3A).  To determine the ability of the DCs to stimulate T cells, freshly 
isolated carboxyfluorescein succinimidyl ester (CFSE)-labeled OTII T cells were cultured in 
the presence of OVA protein-pulsed Plxnb2-/-, Plxnd1-/-, and wild type splenic DCs for three 
days.  Non OVA-pulsed DCs were used as a negative control.  Proliferation of Vb5+ OTII T 
cells was assessed by flow cytometry.  As shown in Figure 3.3B, Plxnb2-/- and Plxnd1-/- DCs 
are capable of stimulating T cells similarly to wild type.  These data suggest that both Plexin-
B2 and Plexin-D1 are dispensable during in-vitro activation of CD4+ T cells by DCs.  
 
Plexin-B2 and Plexin-D1 do not affect the migration of DCs 
 Plexins and semaphorins have been implicated in migration of many different cell 
types including neuronal, endothelial, and immune cells (Kruger et al. 2005).  In zebrafish 
angioblast cells, knockdown of Plexin-B2 or its ligand Semaphorin-3E yields delayed 
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sprouting of intersegmental (ISV) angioblast during development (Lamont et al. 2009).  
Knockdown of Plexin-D1 in zebrafish embryos results in an opposite effect of early ISV 
sprouting (Lamont et al. 2009).  In the mouse nervous system, Plxnb2-/- animals show defects 
in neuronal cell homing that result in neural tube closure defects and cerebellum 
disorganization (Friedel et al. 2007).  Plexin-D1 is required for endothelial cell patterning 
(Gu et al. 2005) as well as migration of DP thymocytes from the cortex into the medulla 
during thymic maturation (Choi et al. 2008).  Therefore we investigated the ability of Plxnb2-
/- and Plxnd1-/- DCs to migrate towards chemokines that are associated with lymph node 
homing CXCL12 and CCL19 (Takamatsu et al. 2010).  Transwell assays of DCs and 
CXCL12 (Fig. 3.4A), CCL19 (Fig. 3.4B) show that both Plxnb2-/- and Plxnd1-/- DCs migrate 
similarly to wild type.  To further investigate the migration and homing capabilities of DCs 
deficient in Plexin-B2 or Plexin-D1, we visualized macrophages, DCs, and B cells in the 
spleens of Plxnb2-/-, Plxnd1-/-, and wild type reconstituted mice.  In Fig. 3.4C, we found that 
CD11b+ macrophages, CD11c+ DCs, and B220+ B cells were present in similar architecture 
in Plxnb2-/-, Plxnd1-/-, and wild type spleens.  Our data show that Plexin-B2 and Plexin-D1 
do not affect migration towards lymph node homing cytokines or architecture of DCs, 
macrophages, or B cells to the spleen. 
 
Plxnb2-/- and Plxnd1-/- DCs are negative regulators of IL-12/IL-23p40. 
To further assess development of Plxnb2-/- and Plxnd1-/- DCs, we stimulated BMDCs 
from Plxnb2-/-, Plxnd1-/-, and wild type animals with LPS.  We determined expression of co-
stimulatory molecules on the surface of DCs.  Surface levels of CD40, CD80, CD86, and I-
 73 
Ab were equivalent between wild type, Plxnb2-/- and Plxnd1-/- mice at both the basal level 
and post activation.   
To characterize DC activation we performed ELISAs of the common cytokines that 
are associated with DC function including IL-6, TNFα, and IL-12/IL-23p40.  Supernatants 
were collected from treatment of DC cultures that were treated with LPS, P3C, and anti-
CD40.  As shown in Figure 3.5A, we determined that levels of IL-6 and TNFα that were 
released in the culture supernatants were equivalent between Plxnb2-/-, Plxnd1-/-, and wild 
type DCs.  However, we observed that levels of IL-12/IL-23p40 were higher in both Plxnb2-/- 
and Plxnd1-/- DCs compared to wild type levels in CD40L stimulated, LPS treated, or 
unstimulated DCs.  
Taken together, these data suggest that despite expression of Plexin-B2 and Plexin-
D1 by the DC population and their upregulation post activation, these proteins are not 
required for expression of costimulatory molecules on the surface of DCs post activation or 
for production of IL-6 and TNFα.  Instead, Plexin-B2 and Plexin-D1 are required for the 
negative regulation of IL-12/IL-23p40 by DCs. 
 
DISCUSSION  
In this study, we characterize the expression of Plexin-B2, Plexin-D1, and 
Semaphorin-3E in various immune cell types.  We report that Plexin-B2 is expressed early in 
development of BMDCs, decreases, and then increases at maturation and with treatment of 
TNFα or LPS but not TLR ligands.  Plexin-B2 is highly expressed by pDCs. The bi-modal 
expression pattern in cDCs and high expression in pDCs of Plexin-B2 is opposite that of 
Plexin-D1.  Plexin-D1 expression increases in myeloid DCs throughout maturation, and is 
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not expressed on pDCs.  Expression of Plexin-D1 by myeloid DCs is increased when these 
cells are activated in the presence of TLR agonists.  Expression studies of a ligand for Plexin-
B2 and Plexin-D1, Semaphorin-3E, revealed that Semaphorin-3E is highly expressed by 
Th2-type T cells and DCs.  Based on differential expression of Plexin-B2 and Plexin-D1 on 
DCs and previous studies demonstrating a role for Plexin-D1 in thymocyte development 
(Choi et al. 2008), we hypothesized that absence of Plexin-B2 and/or Plexin-D1 would lead 
to abnormal T cell-DC interactions.  
Although a role for Plexin-D1 in the thymocyte migration has been previously 
reported, these studies do not address the role of Plexin-D1 in T cell activation during 
immune responses (Choi et al. 2008).  Studies of other plexins have demonstrated that 
plexins can have a profound impact on T cell-DC interactions.  For example, Plexin-A1 
deficient DCs result in an 85% reduction of T cell proliferation in response to antigen both 
in-vitro and in-vivo (Wong et al. 2003; O'Connor et al. 2008).  Our analysis of Plxnb2-/- and 
Plxnd1-/- mice did not reveal a role for Plexin-B2 or Plexin-D1 in antigen uptake by DCs or 
transgenic T cell proliferation in response to antigen.  These findings suggest that while other 
plexins are required for T cell proliferation, Plexin-B2 and Plexin-D1 likely participate in 
other functions of DCs. 
Plexins and semaphorins mediate cell migration in the immune system.  Plexin-C1 is 
expressed on DCs and facilitates inhibition of chemokine induced migration when bound to 
ligand (Walzer et al. 2005).  Plexin-A1 is required for transmigration of DCs across 
lymphatic endothelial cells yet is dispensable for chemokine induced migration in-vitro 
(Takamatsu et al. 2010).  DCs migrate towards the lymph node homing chemokines CXCL12 
and CCL19 upon maturation.  Our studies show that Plexin-B2 and Plexin-D1 do not play a 
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role in migration towards lymph node homing cytokines.  We also show that in steady state 
DC cell number and pattern in the spleen are similar between Plxnb2-/-, Plxnd1-/-, and wild 
type.  DCs are very dynamic in their migration patterns throughout maturation and activation 
in-vivo, and this cannot necessarily be mimicked in-vitro.  Future studies should address a 
role for migration of Plexin-B2 and Plexin-D1 in-vivo.  Studies in-vivo may reveal that 
Plexin-B2 and Plexin-D1 are involved in migration under specific conditions such as 
activation by pathogen or in specific immune environments. 
To further investigate the roles of Plexin-B2 and Plexin-D1 in DC activation, we 
assayed cell surface markers and cytokine production by Plxnb2-/- and Plxnd1-/- DCs.  Our 
data show that Plexin-B2 and Plexin-D1 are not required for upregulation of activation 
markers CD40, CD80, CD86, or I-Ab in response to LPS induced activation.  However, in 
untreated conditions and in response to LPS both Plxnb2-/- and Plxnd1-/- DCs show increased 
levels of IL-12/IL-23p40.  Levels of TNFα and IL-6 are not affected by Plexin-B2 or Plexin-
D1, revealing that this effect is specific for IL-12/IL-23p40.  Future studies should address if 
both IL-12 and IL-23, which share the common p40 subunit, are affected by both Plexin-B2 
and Plexin-D1.  Downstream physiological consequences of overproduction of IL-12/23p40 
in Plxnb2-/- and Plxnd1-/- mice, including Th skewing, response to pathogen, and potential 
pathways that mediate this effect should be assessed.   
In summary, our studies reveal that Plexin-B2 and Plexin-D1 are differentially 
expressed in DCs, yet both mediate negative regulation of IL-12/IL-23p40.  These findings 
suggest crosstalk between the signaling pathways of Plexin-B2 and Plexin-D1 in DCs, 
similar to that previously reported in zebrafish angioblast (Lamont et al. 2009).  The data 
suggest Plexin-B2 and Plexin-D1 function at different times of development of the DC and 
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may also function in different environments or under different cellular conditions.  The 
differential expression of Plexin-B2 and Plexin-D1 demonstrate that control of cell processes 
by plexins may be determined by their expression. 
 
MATERIALS AND METHODS  
Mice  
C57BL/6 and congenic C57BL/6 CD45.1 mice were obtained from the National Cancer 
Institute (Boston, MA).  Plxnd1+/- mice were a gift from Dr. Thomas Jessell’s laboratory and 
have been described (Gu et al. 2005).  Plxnb2+/- mice were a gift from Dr. M. Tessier-
Lavigne and have been described (Friedel et al. 2007).  Plxnb2+/- and Plxnd1+/- mice were 
backcrossed in house at least 10 generations.  OT-II mice (B6.Cg.Tg(TcraTcrb)425Cbn/J), 
specific for the ovalbumin residue 323-339, were obtained from the Jackson Laboratory (Bar 
Harbor, ME).  Mice were housed in a pathogen-free barrier facility at University of North 
Carolina.  These studies were approved by the University of North Carolina Animal Care and 
Use Committee.  For fetal liver chimeras Plxnd1+/- or Plxnb2+/- mice were crossed for over 
10 generations with C57BL/6 mice and intercrossed to obtain -/- and +/+ embryos.  Fetal livers 
were prepared from E14 embryos post PCR genotyping as previously described (Gu, 
Yoshida et al. 2005).  Fetal liver cells were injected (iv) into lethally irradiated C57BL/6 
CD45.1 mice.  Mice were analyzed 6-10 weeks post reconstitution.  Mice were allowed to 
reconstitute for 6-8 weeks before use.   
 
ELISA 
Splenic DCs were isolated from wild type, Plxnb2-/- and Plxnd1-/- animals and were 
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stimulated for 24 hours in the presence Pam3Cys or LPS.  The culture supernatants were 
tested for IL6, TNFα, and IL-12/IL-23p40 cytokine levels by ELISA (Ebioscience, San 
Diego, CA).  
 
Antibodies and FACS 
Monoclonal Abs included: B220 (RA3-6B2), CD23 (B3B4) and APC-Alexa750-conjugated 
streptavidin from BD Pharmingen (San Diego, CA); CD45.2 (104), CD4 (L3T4), CD8 (Ly-
2), IFNgXMG1.2), IL2 (JES6-5H4), IL4 (11B11), CD3 (145-2C11), CD28 (37.51), CD62L 
(MEL-14), GL7 (Ly-77), CD11b (M1/70), CD11c (N418), CD21 (eBio8D9) and TCRβ 
(H57-597) from eBioscience (San Diego, CA).  Secondary antibodies included anti-FITC-
Alexa488 and Alexa405-conjugated streptavidin from Invitrogen (Carlsbad, California).  
Single cell suspensions of different tissues were counted and 106 cells were suspended in 
FACS buffer (1xPBS plus 2% FBS) and stained with various antibody combinations.  All 
flow cytometry was performed on a FACSCalibur and analyzed with FlowJo software (Tree 
Star).  
 
RT-PCR and Quantitative RT-PCR analysis  
RNA was isolated from tissues or sorted resting T cell populations (CD62Lhi CD4+ T cells, 
CD62LhiCD8+ T cells) as well as Th0, Th1 and Th2 cells using a Qiagen RNA extraction kit.  
cDNA was synthesized using SuperScript III reverse transcriptase (Invitrogen).  Primers used 
for RT-PCR and real-time PCR analysis were: HPRT, 5’-GCTGGTGAAAAGGACCTCT-3’, 
5’-CACAGGACTAGAACA CCTGC-3’; Plxnb2 5’- CTAGACATCCCTGAGTCACG-3’, 
5’- AGTCAGCAGTGATGCAAAGT-3’; Plxnd1, 5’-CCTGGGTCACCTCTGTGTTT-3’, 5’-
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TATCTGTCAGGCAGGGGTTC-3’; and Semaphorin3E, 5’-
AGGCCCTGAATACCACTGGTC-3’, 5’-GGTTCCTGTGCCAGCAAAGT-3’.  
Quantitative real-time PCR was performed using SYBR Green reagent in a BIORAD 
iCycler.  
 
Cell culture  
T cell activation: Th1 vs. Th2 skewing was conducted as follows. Sorted CD62Lhi CD4+ 
naive splenic T cells (2x106 cells/ml) were cultured for 3 days with immobilized anti-CD3 
(5mg/ml) and anti-CD28 (5mg/ml) in the presence of anti-IL4 (10mg/ml) and IL-12 
(10ng/ml) (Th1-skewing conditions) or in the presence of anti-IFNγ (10mg/ml) and IL-4 
(10ng/ml) (Th2-skewing conditions.  DC culture: Murine bone marrow DCs were isolated 
from wild type, Plxnb2-/-, or Plxnd1-/- mice and were cultured in the presence of GM-CSF 
and IL-4 as previously described (van Deventer et al. 2002).  T cell culture: T cells from OT-
II mice and purified by negative selection (STEMCELL). DC:T cell co-cultures: DCs were 
harvested at day 10 and pulsed overnight with 50mg/ml OVA (Sigma-Aldrich).  200,000 
DCs were then washed and cultured in a 1:10 ratio with T cells from OT-II transgenic T cells 
in 6 well plates.  
 
Histology  
Spleens of naïve Plxnb2-/- and Plxnd1-/- mice were embedded in OCT compound, snap 
frozen, and stored at -80°C.  5 mm sections were prepared and fixed with 1:1 
Acetone:Methanol for 10 min at -20°C and labeled with various combinations of 
fluorescently labeled CD11b, CD11c, TCRb and B220 mAb.  FITC signal was amplified 
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using anti-FITC-Alexa488 mAb.  Streptavidin-AlexaFluor405 was used to amplify B220-
biotin signal (blue). Images were acquired using a Zeiss LSM 710 confocal 
immunofluorescent microscope. 
 
Statistical analysis  
Statistical significance was determined with two-tailed Student’s t test or analysis of variance 
(ANOVA).  All p values less than 0.05 were considered significant.  
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Figure 3.1 
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Figure 3.1.  Plexin-B2, Plexin-D1, and Semaphorin-3E expression.   
(A) Expression of Plxnb2 in splenic DCs, BMDCs at day 6 (D6) and day 10 (D10), D10 post 
16 hour activation by TLR ligands P3C (1 ug/ml), (LPS (1 ug/ml), CpG (4 ug/ml), TNF (20 
ng/ml), CD40L (1 ug/ml), and plasmacytoid DCs (pDCs) as measured by real-time PCR. 
Data are representative of three independent experiments.  (B) Expression of PlxnB2 in BM-
derived pDCs and cDCs at D3, D6, and D10.  Green lines indicate IgG control antibody 
staining, red histograms are Plxnb2 antibody staining.  (C) Expression of Plxnd1 in sDCs, 
BM-derived DCs D6, D10, post activation, and pDC as measured by real-time PCR.  (D) 
Expression of Sema3E in sorted naïve and activated T cell and B cell populations, and DCs.  
Data are representative of 3 independent experiments.  
 82 
Figure 3.2 
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Figure 3.2.  Schematic of fetal liver transplant. 
Plxnb2+/- or Plxnd1+/- mice are crossed and fetal livers of wild type or Plxnb2-/- or Plxnd1-/- 
embryos are harvested at day 14 of gestation.  Fetal liver cells are harvested by 
homgenization.  2 x 106 fetal liver cells are then transplanted into lethally irradiated congenic 
CD45.1+ mice by tail vein injection.  Animals reconstitute the immune system with donor 
cells for six to eight weeks post transplant. 
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Figure 3.3 
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Figure 3.3.  Plxnb2-/- and Plxnd1-/- DCs efficiently stimulate antigen specific T cells.  
(A) OVA uptake for Plxnb2-/-, Plxnd1-/-, and wild type DCs.  DCs were isolated from spleens 
of mice reconstituted with Plxnb2-/-, Plxnd1-/-, and wild type fetal liver cells and cultured in 
the presence of OVA-FITC for 2 hours. OVA uptake was assessed by flow cytometry. Data 
are representative of 2 independent experiments. n=6 mice per group. (B) DCs were isolated 
from spleens of mice reconstituted with Plxnb2-/-, Plxnd1-/-, and wild type fetal liver cells.  
DCs were then co-cultured with OTII-specific T cells in the presence of OVA and T cell 
proliferation was assessed by CFSE dilution 72 hours later using flow cytometry.  Data are 
representative of 3 independent experiments.  n=9 mice per group. 
 86 
Figure 3.4 
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Figure 3.4.  Plxnb2-/- and Plxnd1-/- DCs migrate similarly to WT control towards 
chemokine gradients.   
(A) Purified wildtype (black bar), Plxnb2-/- (grey bar), and Plxnd1-/- (open bar) DCs were 
placed in upper wells and subjected to in-vitro migration assays in the presence of medium 
alone, CXCL12 and CCL19.  Migrated cells were quantified by toxilight (Lonza, Basel, 
Switzerland) according to the manufacturers instructions and normalized to a standard curve 
n=6-7 mice per group.  (B) Five mm sections of spleens from wildtype, Plxnb2-/- and Plxnd1-
/- mice were labeled with B220-AF350 (blue), CD11b-PE (red) and CD11c-FITC (green).  
FITC signal was amplified using anti-FITC-AF488.  Images were acquired using a Zeiss 
Axiovert 200M confocal immunofluorescent microscope.  n=3 mice per group. 
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Figure 3.5 
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Figure 3.5.  Plxnb2-/- and Plxnd1-/- DCs overproduce IL-12/IL-23p40.  
(A) Plxnb2-/- and Plxnd1-/- DCs are able to upregulate cell surface receptors.  DCs were 
derived in the presence of GM-CSF and IL4 from the bone marrow of mice reconstituted 
with Plxnb2-/-, Plxnd1-/-, and wild type fetal liver cells.  DCs were then cultured in the 
presence of LPS and cell surface receptor expression was assessed 24 hours later using flow 
cytometry.  Data are representative of 3 independent experiments. n=6 mice per group.  (B) 
Plxnb2-/- and Plxnd1-/- DCs are able to produce inflammatory cytokines in response to TLR 
stimuli and anti-CD40.  DCs were cultured in the presence of LPS and anti-CD40 for 24 
hours.  Culture supernatants were assessed for cytokine production by ELISA.  Data are 
representative of 3 independent experiments.  n=3 - 4 mice per group. 
 
 
 
 
 
Chapter 4: Conclusions and Future Directions 
 
Plexin-B2 Expression in the Immune System 
 Data in Chapters 2 and 3 show that Plexin-B2 is expressed in macrophages, cDCs, 
and pDCs.  This is the first report of Plexin-B2 expression in defined populations of the 
innate immune system.  Our data show that Plexin-B2 is highly expressed on both peritoneal 
and bone marrow-derived macrophages yet its expression is not modulated by stimulation 
with TLR agonist to activate the macrophages.  This expression pattern suggests that Plexin-
B2 is active throughout the life cycle of the dendritic cell and may mediate functions during 
quiescence as well as cellular activation.  Macrophages also express Plexins-A1- A3 (Ji et al. 
2009).  In contrast to Plexin-B2, the expression level of Plexins-A1-A3 increases throughout 
M-CSF stimulated maturation.  M-CSF stimulated maturation yields an M2, alternatively 
activated, less inflammatory type of macrophage.  The increase in Plexin-A1-A3 expression 
suggests function during M-CSF maturation that might be less inflammatory and more 
related to the modulation of adaptive immunity.  As an example, Plexin-A1 expression is 
reduced upon activation of macrophages with LPS, which results in a more inflammatory, 
classically activated M1 type of macrophage (Judas et al. 2003; Ji et al. 2009).  We and 
others have indeed confirmed that a major function of Plexin-A1 is in T cell activation. This 
expression pattern is in contrast to Plexin-A4, which is high on both immature and M-CSF 
matured macrophages, suggesting a more constant level of function (Ji et al. 2009) .  Thus, 
modulation of plexin expression in macrophages may serve as a method of regulating plexin 
signaling throughout cell maturation and activation.  Studies of Plexin-B2 should compare its 
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expression pattern in macrophages to an exhaustive study of expression of other plexins in 
macrophages throughout maturation and activation.  This data would yield a more complete 
understanding of plexins that are active at specific stages in macrophage maturation, 
polarization, or activation state.  Additional studies addressing the expression of plexins in 
macrophages from different sites in the body and during conditions such as tumorgenesis, 
angiogenesis, and immune response may also provide important clues as to the function of 
plexins in macrophages. 
 In contrast to macrophages, Plexin-B2 expression is modulated throughout the life 
cycle of the BM-derived cDC.  In cDCs derived from cultures of bone marrow with GM-CSF 
and IL-4, Plexin-B2 is expressed in a bi-phasic fashion.  It is expressed early in maturation, is 
reduced at mid-maturation, and then is slightly upregulated at maturation.  In pDCs derived 
from FLT3L supplemented bone marrow cultures, expression of Plexin-B2 is upregulated in 
the early stages of maturation and continues to remain at high levels throughout maturation.  
The pDC is most similar to macrophages in expression pattern in that Plexin-B2 expression 
remains unabated with maturation.  These data suggest that Plexin-B2 might be functionally 
active during the lifespan of macrophages and pDCs, but its function might be more specific 
to the early and late maturation stages of cDC.  However, in ex-vivo splenic cDCs, Plexin-B2 
is more highly expressed, suggesting that culture conditions may alter plexin expression in 
cells, and this must be carefully considered during experimental design. 
  Plexin-A1 is one of the better studied plexins in the immune system.  It is expressed 
on cDCs and is modulated throughout maturation.  Plexin-A1 levels are very low at the early 
and mid stages of maturation, and quickly spike at later stages and with TNFα (Wong et al. 
2003).  Plexin-A1 is not expressed in macrophages (Wong et al. 2003) nor pDCs (Eun, 
 92 
unpublished observation), suggesting a cDC specific function.  Intriguingly, one of the 
ligands for Plexin-A1, Sema6D, does not appear on T cells until the later stages of cell 
proliferation that occurs in response to antigen presentation by the DC (O'Connor et al. 
2008).  Without Plexin-A1 T cell proliferation is stopped at late stage (O'Connor et al. 2008).  
Plexin-A1 is also required for entry of DCs into the lymphatic system through another ligand, 
Sema3A (Takamatsu et al. 2010).  This example highlights how timing of expression of both 
plexins and their ligands are critical in controlling their signaling responses. 
 
Plexin-B2 in Immune System Development 
 Plexins and their ligands are important in development of the nervous and vascular 
systems.  For example, Plexin-A2 and its ligand Nueropilin-2 mediate cell migration and cell 
homing during development at the interface of the peripheral and central nervous system 
(Chauvet et al. 2008).  Deficiency of Plexin-D1 or its vascular system ligand Semaphorin-3A 
result in embryonic lethality in the mouse due to defects in vascular patterning (Gitler et al. 
2004; Gu et al. 2005).  Plexin-B2 is critical during embryogenesis in the nervous system 
(Friedel et al. 2007).  Plxnb2-/- mice display severe neural tube closure defects that result in 
exencephaly and embryonic lethality (Friedel et al. 2007; Hirschberg et al. 2010).  The 
defects in neural tube closure are attributed to defects in cell migration and homing (Friedel 
et al. 2007).  Based on the expression of Plexin-B2 on innate immune cells, we hypothesized 
that Plexin-B2 may have an effect on immune system development.   
To study the formation of the immune system in embryonic lethal mice, we created 
fetal liver chimeric mice from wild type and Plxnb2-/- fetal livers.  As discussed in Chapter 2, 
the immune system of Plxnb2-/- mice is reconstituted normally in both the splenic and bone 
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marrow compartments.  Fetal liver transplants into Ly5.2+ mice reveal that percent of B220+ 
B cells, CD11c+ cDCs, PDCA-1+ / B220+ pDCs, and F4/80+ macrophages found in spleen are 
equivalent between wild type and Plxnb2-/- reconstituted mice.  T cell and NK cell 
development is normal, as TCR+CD4+, TCR+CD8+, NK1.1+CD4+ NKT cells, and NK1.1+ 
cell percentages are equivalent. The data in Chapter 3 show that the architecture of 
macrophages, dendritic cells, and B cells of Plxnb2-/- spleens are normal compared to wild 
type.  The finding that immune system development and homing are normal in the Plxnb2-/- 
mouse is surprising, given the extreme defects found in the nervous system of these mice.  It 
is possible that non-immune expression of Plexin-B2 in the recipient mouse is enough to 
mask any Plexin-B2 related defects in immune development and homing.  It is also possible 
that under different conditions of pathologic or beneficial immune activation, such as 
development of autoimmunity, cancer, or immune response to pathogen, a defect in Plxnb2-/- 
immune cell homing or proliferation could be observed.  Future Plexin-B2 studies should 
address more functional aspects of DCs and macrophages, as well as immune system 
development in response to stimulation and pathogens. 
 
Small GTPases and Plexin-B2 
As described in Chapter 2, Plexin-B2 is a negative regulator of the GTPases, Rac and 
Cdc42, but not Rho in macrophages.  Extensive studies of the closely related Plexin-B1 have 
demonstrated that Plexin-B1 is a critical regulator of not only Rac and Rho, but also M-Ras 
and R-Ras GTPases (Driessens et al. 2002; Vikis et al. 2002; Oinuma et al. 2004; Saito et al. 
2009).  Plexin-B1 regulation of Rho has also been shown to require Rnd1 GTPase (Oinuma 
et al. 2003).  The functional outcome of the Plexin-B1 regulation of the Rho family of 
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GTPases is very finely regulated modulation of the actin cytoskeleton and cell motility.  
Other plexins have also been found to mediate Rho family GTPase signaling.  Plexin-A1 
modulates antigen specific T cell proliferation through interaction with Rho but not Rac or 
Cdc42 (Eun et al. 2006).  Both Plexin-D1 and Plexin-C1 function as R-Ras GAPs to inhibit 
migration, but differ in their requirement for Rnd2 to mediate this function (Uesugi et al. 
2009).  Both plexins serve similar functions yet are regulated in this function by Rnd2, 
allowing for very finely controlled regulation of R-Ras. 
 Obvious questions regarding the function of Plexin-B2 in regulation of small 
GTPases can be raised.  Does Plexin-B2 regulate M-Ras and R-Ras similar to Plexin-B1?  
Does Plexin-B2 regulation of R-Ras require Rnd1 or Rnd2, and what are the downstream 
consequences?  What differentiates Plexin-B2 signaling from Plexin-B1 signaling?  Studies 
should examine other macrophage plexins and their influence on Rho family GTPases.  It is 
possible that plexins interact with each other and/or with ligand to regulate RhoGTPase 
signaling?  Studies have shown that Plexin-A1 and Plexin-B1 interact in their cytoplasmic 
domains, and are thought to cooperate in signaling (Usui et al. 2003).  In zebrafish embryos 
the signaling pathways of Plexin-B2 and Plexin-D1 antagonize each other to control 
sprouting behavior of angioblast (Lamont et al. 2009).  A complete understanding of how 
plexins as a group mediate cell movement, response to pathogen, proliferation, or survival 
cannot be ascertained by studying plexins individually.  Studies of plexins as a family will 
provide a more complete understanding of the intricacies of plexin signaling. 
 
Plexin-B2 and its Effects on Phagocytosis 
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In macrophages, FcRγ mediated phagocytosis requires Rac and Cdc42 (Cox et al. 
1997).  Data in Chapter 2 shows that Plxnb2-/- macrophages have more active Cdc42 and Rac 
in steady state than wild type.  We hypothesized that Plexin-B2 may play a role in uptake of 
opsonized T cells, E. coli, or latex beads.  However out data show that macrophages are not 
defective in their uptake of Ig-coated T cells, E. coli, or latex beads, suggesting that Plexin-
B2 does not regulate signaling that occurs during Fc-mediated phagocytosis.  These data 
demonstrate that Plexin-B1 control of Rac is very specific.  It is possible that FcγR signaling, 
while dependant on Rac and Cdc42, functions independently of Plexin-B2 regulation of Rac 
signaling.  Thus the two pathways may converge at Rac but not influence each other.  These 
questions could be answered by examining how Plexin-B2 affects RacGTP levels during the 
phagocytic process.  These results may show that Plexin-B2 regulation of Rac and Cdc42 
functions independently of FcγR mediated modulation of Rac.  Studies of Sema3A, which 
has been shown to inhibit actin cytoskeleton reorganization, does not affect phagocytosis in 
macrophages (Dent et al. 2004; Ji et al. 2009).  However, Plexin-C1 has been shown to 
inhibit phagocytosis upon binding to its viral ligand Poxvirus A39R (Walzer et al. 2005).  It 
is possible that because there is more already more active Cdc42 and Rac in Plxnb2-/- cells, 
and phagocytosis also induces activation of Rac and Cdc42, that additive active Rac and 
Cdc42 do not result in additional phagocytosis (Beemiller et al. 2010). 
 
Plexin-B2 and Cytokine Secretion 
The plexin family has been implicated in control cytokine secretion in the immune 
system.  Plexin-A1 regulates Type I IFN-α through association with PDC-TREM in pDCs 
(Watarai et al. 2008).  Sema4D deficient DCs are unable to produce IL-12 compared to wild 
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type DCs (Kumanogoh et al. 2002).  Sema7A induces inflammatory cytokine production in 
macrophages through its integrin receptor α1β1 (Suzuki et al. 2007).  We hypothesized that 
Plexin-B2 may also regulate cytokine secretion in DCs and macrophages.  Data in Chapter 2 
shows that Plxnb2-/- macrophages secrete normal amounts of IL-6 and TNFα in response to 
TLR ligands Poly(I:C), LPS, and R837.  Data presented in Chapter 3 shows that Plxnb2-/- ex-
vivo dendritic cells secrete normal amounts of IL-6 and TNFα in response to LPS and anti-
CD40 antibody, but are overactive in their response to IL-12/IL-23p40 both without 
stimulation and in response to LPS.  
IL-12/IL-23p40 subunit contributes to the active forms of both IL-12 and IL-23, or 
can exist as a homodimer or monomer.  The IL-12 pathways leads to a Th1 response, while 
the IL-23 pathway leads to induction of Th17 cells (reviewed in Gee et al. 2009).  
Intriguingly, the IL-12/IL-23p40 subunit has been shown to exist in-vivo as a monomer or 
dimer of itself and is present in excess of IL-12 or IL-23, and is suggested to function as a 
negative regulator if IL-23 and/or IL-12 signaling (reviewed in Cooper et al. 2007).  The 
monomer form of IL-12p40 is required for dendritic cell migration in response to 
Mycobacterium tuberculosis infection (Khader et al. 2006).  Determining the exact form of 
IL-12/IL-23p40 protein(s) that are negatively regulated by Plexin-B2 and Plexin-D1 is a 
critical next step in understanding this finding and its immune consequence. 
 These data in the context of data from the field demonstrate that plexin control of 
cytokine secretion is very specific.  Plexins may couple environmental and attachment cues 
to inflammatory conditions so that cells respond only when in the correct location or in 
contact with the correct cells. 
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Plexin-B2 and Migration 
Chapter 2 demonstrates the Plexin-B2 negatively regulates macrophage motility but 
not directed migration.  Most plexins have been shown to mediate migration or motility.  It is 
interesting that many cells express more than one plexin, yet most plexins mediate cell 
movement.  Are different plexins activated at different locations within the body or within 
specific locations on the cell?  Are plexins so important for cell movement that they are 
redundant?  Do different cytokines or cell-cell contacts result in activation of different plexin 
signaling pathways?  These questions are very complex and are not easily addressed by 
individual knockout studies, as simply taking out a gene may induce others or eliminate 
interactions of plexins with each other.  Studies of Plexin-B2 and other plexins that are 
fluorescently labeled and can be observed in real time within the cell, similar to the biosensor 
studies used in the study of RhoGTPases at the leading edge of a cell (Machacek et al. 2009), 
would provide more answers to these complex questions. 
 
Plexin-B2 and Cancer Biology 
Mutations in Plexin-B1 that interfere with its ability to bind and regulate Rac have 
been identified in one study in 89% of percent of human prostate cancer samples with bone 
metastases (Wong et al. 2007).  Plexin-B2 contains many of the same mutation sites as 
Plexin-B1, and may contribute to cancer by a similar mechanism.  Plexin-B2 has been 
identified in the cells of vascular, brain, epithelial, and endocrine systems origin by immuno-
staining of sections of tissue (Friedel et al. 2007; Zielonka et al. 2010)  Thus mutations in 
Plexin-B2 could result in inappropriate regulation of many different cell types that have 
potential of overgrowth within the body.  
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Many other Plexins have been recently linked to cancer.  Overexpression of Sema3E 
increases invasion and metastasis in tumor cells through its receptor Plexin-D1 in complex 
with ErbB2 (Casazza et al. 2010).  Expression of Plexin-B3 and its receptor Sema5A increase 
from normal tissue to lymph node metastases in gastric carcinoma samples (Pan et al. 2009).  
Molecular profiling of melanoma and pancreatic cancer cells show that multiple plexins have 
loss of function mutations that increase progression (Casazza et al. 2010).  These studies 
suggest that Plexins have regulatory roles across broad types of cancers.  Understanding how 
the plexin interactions combine with other mutations in cancer may allow for development of 
drugs targeting the plexins or increased detection of metastatic cells.  Regulating the 
activation state by use of their ligand or other biological mimic is a potential strategy for 
targeting cancer cells and their ability to move or invade. 
 
Plexins and Semaphorins- Future Directions 
One of the most critical questions remaining to be answered is why and if plexin 
proteins function differently depending on the cell type.  Plexins can be tyrosine 
phosphorylated, are found at the cell surface, and can function in conjunction with growth 
factor receptors.  This makes them potential drug targets for the treatment of diseases such as 
cancer and autoimmunity.  However, it is critical to understand how the immune, nervous, 
and other systems mediate responses to plexins and semaphorins.  For example, does Plexin-
A1 function differently in the nervous system due to availability of ligand, expression of co-
receptors, or expression differences of individual plexins or groups of plexins?  B family 
plexins are capable of being cleaved by proprotein convertases in overexpression studies 
(Artigiani et al. 2003), suggesting that Plexin-B2 is capable of both long distance and local 
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signaling.  Alternatively, secreted Plexin-B2 may function to block secreted semaphorin 
ligand(s), such as Sema4D.  Understanding how plexin and semaphorin signaling is 
differentially regulated between different body systems may provide data that would allow 
for creation of drugs that target only plexin or semaphorin signaling in one body system but 
not others.  For example, Semaphorin-3A has been tested as a drug treatment in a rodent 
model of atopic dermatitis, where it was found to reduce disease (Yamaguchi et al. 2008).  
The effects of Semaphorin-3A on the brain were not assessed in this study.  Semaphorin-3A 
has been shown to induce cell death in cortical neurons of adult mice (Jiang et al. 2010), thus 
the side effects of Semaphorin-3A as a drug could be detrimental.  However, if difference in 
signaling components between the two systems could be ascertained, a more targeted drug 
could be created.  Future studies must address the roles of plexins and semaphorins across 
multiple body systems. 
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